JOHNSON & JOHNSON, 10-Q filed on 7/24/2025
Quarterly Report
v3.25.2
Cover - shares
 6 Months Ended
Jun. 29, 2025
Jul. 18, 2025
Entity Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 29, 2025  
Document Transition Report false  
Entity File Number 1-3215  
Entity Registrant Name Johnson & Johnson  
Entity Incorporation, State or Country Code NJ  
Entity Tax Identification Number 22-1024240  
Entity Address, Address Line One One Johnson & Johnson Plaza  
Entity Address, City or Town New Brunswick  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 08933  
City Area Code 732  
Local Phone Number 524-0400  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   2,408,338,872
Entity Central Index Key 0000200406  
Current Fiscal Year End Date --12-28  
Document Fiscal Year Focus 2025  
Document Fiscal Period Focus Q2  
Amendment Flag false  
Common Stock, Par Value $1.00    
Entity Information [Line Items]    
Title of 12(b) Security Common Stock, Par Value $1.00  
Trading Symbol JNJ  
Security Exchange Name NYSE  
1.150% Notes Due November 2028    
Entity Information [Line Items]    
Title of 12(b) Security 1.150% Notes Due November 2028  
Trading Symbol JNJ28  
Security Exchange Name NYSE  
2.700% Notes Due February 2029    
Entity Information [Line Items]    
Title of 12(b) Security 2.700% Notes Due February 2029  
Trading Symbol JNJ29B  
Security Exchange Name NYSE  
3.20% Notes Due November 2032    
Entity Information [Line Items]    
Title of 12(b) Security 3.200% Notes Due June 2032  
Trading Symbol JNJ32  
Security Exchange Name NYSE  
3.050% Notes Due February 2033    
Entity Information [Line Items]    
Title of 12(b) Security 3.050% Notes Due February 2033  
Trading Symbol JNJ33B  
Security Exchange Name NYSE  
1.650% Notes Due May 2035    
Entity Information [Line Items]    
Title of 12(b) Security 1.650% Notes Due May 2035  
Trading Symbol JNJ35  
Security Exchange Name NYSE  
3.350% Notes Due November 2036    
Entity Information [Line Items]    
Title of 12(b) Security 3.350% Notes Due June 2036  
Trading Symbol JNJ36A  
Security Exchange Name NYSE  
3.350% Notes Due February 2037    
Entity Information [Line Items]    
Title of 12(b) Security 3.350% Notes Due February 2037  
Trading Symbol JNJ37B  
Security Exchange Name NYSE  
3.550% Notes Due November 2044    
Entity Information [Line Items]    
Title of 12(b) Security 3.550% Notes Due June 2044  
Trading Symbol JNJ44  
Security Exchange Name NYSE  
3.600% Notes Due February 2045    
Entity Information [Line Items]    
Title of 12(b) Security 3.600% Notes Due February 2045  
Trading Symbol JNJ45  
Security Exchange Name NYSE  
3.700% Notes Due February 2055    
Entity Information [Line Items]    
Title of 12(b) Security 3.700% Notes Due February 2055  
Trading Symbol JNJ55  
Security Exchange Name NYSE  
v3.25.2
Consolidated Balance Sheets - USD ($)
$ in Millions
Jun. 29, 2025
Dec. 29, 2024
Current assets:    
Cash and cash equivalents (Note 4) $ 18,577 $ 24,105
Marketable securities 303 417
Accounts receivable, trade, less allowances $185 (2024, $167) 17,846 14,842
Inventories (Note 2) 13,412 12,444
Prepaid expenses and other 4,360 4,085
Total current assets 54,498 55,893
Property, plant and equipment at cost 52,472 48,768
Less: accumulated depreciation (30,523) (28,250)
Property, plant and equipment, net 21,949 20,518
Intangible assets, net (Note 3) 49,835 37,618
Goodwill (Note 3) 48,117 44,200
Deferred taxes on income (Note 5) 6,801 10,461
Other assets 12,189 11,414
Total assets 193,389 180,104
Current liabilities:    
Loans and notes payable 11,526 5,983
Accounts payable 9,464 10,311
Accrued liabilities 7,404 8,549
Accrued rebates, returns and promotions 20,823 17,580
Accrued compensation and employee related obligations 3,298 4,126
Accrued taxes on income (Note 5) 1,665 3,772
Total current liabilities 54,180 50,321
Long-term debt (Note 4) 39,235 30,651
Deferred taxes on income (Note 5) 3,799 2,448
Employee related obligations (Note 6) 7,021 7,255
Long-term taxes payable (Note 5) 418 390
Other liabilities 10,263 17,549
Total liabilities 114,916 108,614
Commitments and Contingencies (Note 11)
Shareholders’ equity:    
Common stock — par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) 3,120 3,120
Accumulated other comprehensive income (loss) (Note 7) (14,305) (11,741)
Retained earnings and Additional paid-in capital 165,371 155,791
Less: common stock held in treasury, at cost (713,064,000 and 712,921,000 shares) 75,713 75,680
Total shareholders’ equity 78,473 71,490
Total shareholders’ equity 78,473 71,490
Total liabilities and shareholders’ equity $ 193,389 $ 180,104
v3.25.2
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Jun. 29, 2025
Dec. 29, 2024
Current assets:    
Allowances for doubtful accounts $ 185 $ 167
Shareholders' equity:    
Common stock, par value per share (in usd per share) $ 1.00 $ 1.00
Common stock, shares authorized (in shares) 4,320,000,000 4,320,000,000
Common stock, shares issued (in shares) 3,119,843,000 3,119,843,000
Treasury stock (in shares) 713,064,000 712,921,000
v3.25.2
Consolidated Statements of Earnings - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Jun. 29, 2025
Jun. 30, 2024
Jun. 29, 2025
Jun. 30, 2024
Income Statement [Abstract]        
Sales to customers (Note 9) $ 23,743 $ 22,447 $ 45,636 $ 43,830
Sales to customers percent to sales 100.00% 100.00% 100.00% 100.00%
Cost of products sold $ 7,628 $ 6,869 $ 14,985 $ 13,380
Cost of products sold percent to sales 32.10% 30.60% 32.80% 30.50%
Gross profit $ 16,115 $ 15,578 $ 30,651 $ 30,450
Gross Profit Percent To Sales 67.90% 69.40% 67.20% 69.50%
Selling, marketing and administrative expenses $ 5,889 $ 5,681 $ 11,001 $ 10,938
Selling marketing and administrative expenses percent to sales 24.80% 25.30% 24.10% 25.00%
Research and development expense $ 3,516 $ 3,440 $ 6,741 $ 6,982
Research and development expense percent to sales 14.80% 15.30% 14.80% 16.00%
In-process research and development impairments $ 0 $ 194 $ 0 $ 194
In-process research and development percent to sales 0.00% 0.90% 0.00% 0.40%
Interest income $ (260) $ (395) $ (592) $ (759)
Interest income percent to sales (1.10%) (1.80%) (1.30%) (1.80%)
Interest expense, net of portion capitalized $ 308 $ 270 $ 512 $ 425
Interest expense, net of portion capitalized percent to sales 1.30% 1.20% 1.10% 1.00%
Other (income) expense, net $ 107 $ 653 $ (7,214) $ 3,057
Other (income) expense, net percent to sales 0.50% 2.90% (15.80%) 7.00%
Restructuring (Note 12) $ 64 $ (13) $ 81 $ 151
Restructuring charge percent to sales 0.30% 0.00% 0.20% 0.30%
Earnings before provision for taxes on income $ 6,491 $ 5,748 $ 20,122 $ 9,462
Earnings before provision for taxes on income percent to sales 27.30% 25.60% 44.10% 21.60%
Provision for taxes on income (Note 5) $ 954 $ 1,062 $ 3,586 $ 1,521
Provision for taxes on income percent to sales 4.00% 4.70% 7.90% 3.50%
Net earnings from continuing operations percent of sales 23.30% 20.90% 36.20% 18.10%
Net earnings $ 5,537 $ 4,686 $ 16,536 $ 7,941
NET EARNINGS PER SHARE        
Total net earnings per share - basic (in dollars per share) $ 2.30 $ 1.95 $ 6.87 $ 3.30
Total net earnings per share - diluted (in dollars per share) $ 2.29 $ 1.93 $ 6.82 $ 3.27
Avg. shares outstanding        
Basic (shares) 2,406.3 2,406.8 2,406.7 2,407.5
Diluted (shares) 2,419.1 2,422.0 2,423.3 2,428.5
v3.25.2
Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 29, 2025
Jun. 30, 2024
Jun. 29, 2025
Jun. 30, 2024
Statement of Comprehensive Income [Abstract]        
Net earnings $ 5,537 $ 4,686 $ 16,536 $ 7,941
Other comprehensive income (loss), net of tax        
Foreign currency translation (3,164) (389) (3,739) 1,734
Securities:        
Unrealized holding gain (loss) arising during period (1) (1) (1) 1
Net change (1) (1) (1) 1
Employee benefit plans:        
Prior service cost amortization during period (36) (34) (71) (50)
Gain (loss) amortization during period 79 43 156 111
Net change 43 9 85 61
Derivatives & hedges:        
Unrealized gain (loss) arising during period 25 75 (117) (92)
Reclassifications to earnings 532 (179) 1,208 (430)
Net change 557 (104) 1,091 (522)
Other comprehensive income (loss) (2,565) (485) (2,564) 1,274
Comprehensive income $ 2,972 $ 4,201 $ 13,972 $ 9,215
v3.25.2
Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 29, 2025
Jun. 30, 2024
Jun. 29, 2025
Jun. 30, 2024
Statement of Comprehensive Income [Abstract]        
Foreign currency translation adjustment income (loss) $ 824 $ (65) $ 1,200 $ (684)
Employee benefit plans income (loss) 10 1 21 (41)
Derivatives & hedges income (loss) $ 148 $ (28) $ 290 $ (139)
v3.25.2
Consolidated Statements of Equity - USD ($)
$ in Millions
Total
Retained Earnings and Additional Paid-in Capital
Accumulated Other Comprehensive Income (AOCI)
Common Stock Issued Amount
Treasury Stock Amount
Beginning balance at Dec. 31, 2023 $ 68,774 $ 153,843 $ (12,527) $ 3,120 $ (75,662)
Net earnings 7,941 7,941      
Cash dividends paid (5,854) (5,854)      
Employee compensation and stock option plans 1,015 (570)     1,585
Repurchase of common stock (1,611)       (1,611)
Other (1)       (1)
Other comprehensive income (loss), net of tax 1,274   1,274    
Ending balance at Jun. 30, 2024 71,538 155,360 (11,253) 3,120 (75,689)
Beginning balance at Mar. 31, 2024 70,020 153,378 (10,768) 3,120 (75,710)
Net earnings 4,686 4,686      
Cash dividends paid (2,985) (2,985)      
Employee compensation and stock option plans 438 281     157
Repurchase of common stock (136)       (136)
Other comprehensive income (loss), net of tax (485)   (485)    
Ending balance at Jun. 30, 2024 71,538 155,360 (11,253) 3,120 (75,689)
Beginning balance at Dec. 29, 2024 71,490 155,791 (11,741) 3,120 (75,680)
Net earnings 16,536 16,536      
Cash dividends paid (6,118) (6,118)      
Employee compensation and stock option plans 1,256 (838)     2,094
Repurchase of common stock (2,127)       (2,127)
Other comprehensive income (loss), net of tax (2,564)   (2,564)    
Ending balance at Jun. 29, 2025 78,473 165,371 (14,305) 3,120 (75,713)
Beginning balance at Mar. 30, 2025 78,109 162,635 (11,740) 3,120 (75,906)
Net earnings 5,537 5,537      
Cash dividends paid (3,129) (3,129)      
Employee compensation and stock option plans 519 328     191
Repurchase of common stock (including excise tax) (2)       (2)
Other comprehensive income (loss), net of tax (2,565)   (2,565)    
Ending balance at Jun. 29, 2025 $ 78,473 $ 165,371 $ (14,305) $ 3,120 $ (75,713)
v3.25.2
Consolidated Statements of Equity (Parenthetical) - $ / shares
 3 Months Ended 6 Months Ended
Jun. 29, 2025
Jun. 30, 2024
Jun. 29, 2025
Jun. 30, 2024
Statement of Stockholders' Equity [Abstract]        
Cash dividends paid (in dollars per share) $ 1.30 $ 1.24 $ 2.54 $ 2.43
v3.25.2
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 6 Months Ended
Jun. 29, 2025
Jun. 30, 2024
CASH FLOWS FROM OPERATING ACTIVITIES    
Net earnings $ 16,536 $ 7,941
Adjustments to reconcile net earnings to cash flows from operating activities:    
Depreciation and amortization of property and intangibles 3,715 3,597
Stock based compensation 698 643
Asset write-downs 30 379
Charges for purchase of in-process research and development assets 92 0
Net gain on sale of assets/businesses (74) (223)
Deferred tax provision 2,997 (2,257)
Credit losses and accounts receivable allowances 3 0
Changes in assets and liabilities, net of effects from acquisitions and divestitures:    
Increase in accounts receivable (2,283) (1,163)
Increase in inventories (656) (739)
(Decrease) / Increase in accounts payable and accrued liabilities (886) 449
(Increase)/Decrease in other current and non-current assets (6,194) 3,731
Decrease in other current and non-current liabilities (5,926) (3,068)
Net cash flows from operating activities 8,052 9,290
Cash flows from investing activities    
Additions to property, plant and equipment (1,838) (1,783)
Proceeds from the disposal of assets/businesses, net (Note 10) 332 573
Acquisitions, net of cash acquired (Note 10) (14,458) (14,807)
Acquired in-process research and development assets / related milestones (Note 10) (369) 0
Purchases of investments (431) (1,184)
Sales of investments 953 1,706
Credit support agreements activity, net (2,684) 1,430
Other (including capitalized licenses and milestones) (66) (86)
Net cash used by investing activities (18,561) (14,151)
Cash flows from financing activities    
Dividends to shareholders (6,118) (5,854)
Repurchase of common stock (2,127) (1,611)
Proceeds from short-term debt, net 9,349 13,976
Repayment of short-term debt, net (5,058) (3,915)
Proceeds from long-term debt, net of issuance costs 9,138 6,659
Repayment of long-term debt (754) (803)
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net 557 290
Credit support agreements activity, net (271) 281
Settlement of convertible debt acquired from Shockwave 0 (970)
Other 41 37
Net cash from financing activities 4,757 8,090
Effect of exchange rate changes on cash and cash equivalents 224 (210)
(Decrease) / Increase in cash and cash equivalents (5,528) 3,019
Cash and cash equivalents, beginning of period 24,105 21,859
Cash and cash equivalents, end of period $ 18,577 $ 24,878
v3.25.2
Summary of Significant Accounting Policies
 6 Months Ended
Jun. 29, 2025
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson & Johnson and its subsidiaries (the Company) and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2024. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.
Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.
New accounting standards
The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2024.
Recently adopted accounting standards
There were no new material accounting standards adopted in the fiscal six months of 2025.
Recently issued accounting standards
There were no new material accounting standards issued in the fiscal six months of 2025.
Supplier finance program obligations
The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide enrolled suppliers the ability to finance payment obligations from the Company with the third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The Company’s obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment terms of 90 days), are not affected by a participating supplier’s decision to join in the program.
Confirmed obligations under the program as of June 29, 2025, and December 29, 2024, were $0.7 billion and $0.8 billion, respectively. The obligations are presented as Accounts payable on the Consolidated Balance Sheets.
v3.25.2
Inventories
 6 Months Ended
Jun. 29, 2025
Inventory Disclosure [Abstract]  
Inventories Inventories
(Dollars in Millions)June 29, 2025December 29, 2024
Raw materials and supplies$2,3892,337
Goods in process3,9712,815
Finished goods7,0527,292
Total inventories$13,41212,444
v3.25.2
Intangible Assets and Goodwill
 6 Months Ended
Jun. 29, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets and Goodwill Intangible assets and goodwill
Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2024. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.
(Dollars in Millions)June 29, 2025December 29, 2024
Intangible assets with definite lives:  
Patents and trademarks — gross$53,27244,695
Less accumulated amortization(30,756)(26,124)
Patents and trademarks — net$22,51618,571
Customer relationships and other intangibles — gross21,91020,310
Less accumulated amortization(14,487)(13,544)
Customer relationships and other intangibles — net(1)
$7,4236,766
Intangible assets with indefinite lives:  
Purchased in-process research and development19,89612,281
Total intangible assets — net$49,83537,618
(1)The majority is comprised of customer relationships
Goodwill as of June 29, 2025 was allocated by segment of business as follows:
(Dollars in Millions)
Innovative
Medicine
MedTechTotal
Goodwill at December 29, 2024
$10,69233,50844,200
Goodwill, related to acquisitions2,876—2,876
Goodwill, related to divestitures—(29)(29)
Currency translation/Other7583121,070
Goodwill at June 29, 2025
$14,32633,79148,117
    
The weighted average amortization period for patents and trademarks is approximately 13 years. The weighted average amortization period for customer relationships and other intangible assets is approximately 19 years. The amortization expense of amortizable intangible assets included in the cost of products sold was $1.3 billion and $1.1 billion for the fiscal second quarters ended June 29, 2025 and June 30, 2024, respectively. The amortization expense of amortizable intangible assets included in the cost of products sold was $2.4 billion and $2.2 billion for the fiscal six months ended June 29, 2025 and June 30, 2024, respectively.
The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:
(Dollars in Millions)
20252026202720282029
$4,5004,0003,4002,7002,600
See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.
v3.25.2
Fair Value Measurements
 6 Months Ended
Jun. 29, 2025
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair value measurements
The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges.
Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities.
The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of June 29, 2025, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $5.2 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of June 29, 2025, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $47.7 billion, $40.9 billion and $9.0 billion, respectively. As of December 29, 2024, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $45.1 billion, $40.5 billion and $9.0 billion, respectively.
All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.
The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction.
Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.
The Company designated its Euro denominated notes with due dates ranging from 2028 to 2055 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates.
As of June 29, 2025, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $0.7 billion after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedge contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.
The following table is a summary of the activity related to derivatives and hedges for the fiscal second quarters ended June 29, 2025 and June 30, 2024, net of tax:


June 29, 2025June 30, 2024
(Dollars in Millions)Sales
Cost of
Products
Sold
R&D
Expense
Interest
(Income)
Expense
Other
(Income)
Expense
Sales
Cost of
Products
Sold
R&D
Expense
Interest
(Income)
Expense
Other
(Income)
Expense
The effects of fair value, net investment and cash flow hedging:
Gain (Loss) on fair value hedging relationship:
Interest rate swaps contracts:
    Hedged items$———52————(53)—
    Derivatives designated as hedging instruments———(52)————53—
Gain (Loss) on net investment hedging relationship:
Cross currency interest rate swaps contracts:
   Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing———48————33—
   Amount of gain or (loss) recognized in AOCI———48————33—
Gain (Loss) on cash flow hedging relationship:
Forward foreign exchange contracts:
   Amount of gain or (loss) reclassified from AOCI into income 2(132)(16)—(3)(1)948—3
   Amount of gain or (loss) recognized in AOCI 11466(72)—(29)26611—1
Cross currency interest rate swaps contracts:
   Amount of gain or (loss) reclassified from AOCI into income———76————42—
   Amount of gain or (loss) recognized in AOCI$———108————(38)—
The following table is a summary of the activity related to derivatives and hedges for the fiscal six months ended June 29, 2025 and June 30, 2024, net of tax:


June 29, 2025June 30, 2024
(Dollars in Millions)SalesCost of Products SoldR&D ExpenseInterest (Income) ExpenseOther (Income) ExpenseSalesCost of Products SoldR&D ExpenseInterest (Income) ExpenseOther (Income) Expense
The effects of fair value, net investment and cash flow hedging:
Gain (Loss) on fair value hedging relationship:
Interest rate swaps contracts:
 Hedged items$———240————(45)—
 Derivatives designated as hedging instruments———(240)————45—
Gain (Loss) on net investment hedging relationship:
Cross currency interest rate swaps contracts:
   Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing———98————67—
   Amount of gain or (loss) recognized in AOCI———98————67—
Gain (Loss) on cash flow hedging relationship:
Forward foreign exchange contracts:
   Amount of gain or (loss) reclassified from AOCI into income 1(122)(15)—(3)—25912—1
   Amount of gain or (loss) recognized in AOCI 14571(108)—(40)(1)4733—5
Cross currency interest rate swaps contracts:
   Amount of gain or (loss) reclassified from AOCI into income———158————91—
   Amount of gain or (loss) recognized in AOCI$———673————(243)—
As of June 29, 2025, and December 29, 2024, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges:
Line item in the Consolidated Balance Sheet in which the hedged item is includedCarrying Amount of the Hedged Liability
Cumulative Amount of Fair Value
Hedging Gain/ (Loss) Included in the
Carrying Amount of the Hedged Liability
(Dollars in Millions)June 29, 2025December 29, 2024June 29, 2025December 29, 2024
Long-term Debt$8,2097,935(820)(1,132)

The following table is the effect of derivatives not designated as hedging instruments for the fiscal second quarters ended and fiscal six months ended 2025 and 2024:
Gain/(Loss)
Recognized In
Income on Derivative		Gain/(Loss)
Recognized In
Income on Derivative
(Dollars in Millions)Location of
Gain /(Loss)
Recognized in
Income on Derivative		Fiscal Second Quarter EndedFiscal Six Months Ended
Derivatives Not Designated as Hedging InstrumentsJune 29, 2025June 30, 2024June 29, 2025June 30, 2024
Foreign Exchange ContractsOther (income) expense$(19)204345

The following table is the effect of net investment hedges for the fiscal second quarters ended in 2025 and 2024:
Gain/(Loss)
Recognized In
Accumulated OCI
Location of Gain or (Loss)
Reclassified from Accumulated OCI Into Income		Gain/(Loss) Reclassified From
Accumulated OCI
Into Income
(Dollars in Millions)June 29, 2025June 30, 2024June 29, 2025June 30, 2024
Debt$(803)46Interest (income) expense——
Cross Currency interest rate swaps$(700)92Interest (income) expense——

The following table is the effect of net investment hedges for the fiscal six months ended in 2025 and 2024

Gain/(Loss)
Recognized In
Accumulated OCI		Location of Gain or (Loss)
Reclassified from Accumulated
OCI Into Income		Gain/(Loss) Reclassified From
Accumulated OCI
Into Income
(Dollars in Millions)June 29, 2025June 30, 2024June 29, 2025June 30, 2024
Debt$(1,119)130Interest (income) expense——
Cross Currency interest rate swaps$140820Interest (income) expense——
The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company has elected to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.
The following table is a summary of the activity related to equity investments:
December 29, 2024June 29, 2025
(Dollars in Millions)Carrying Value
Changes in Fair Value Reflected in Net Income (1)
(Sales)/ Purchases/Other (2)
Carrying ValueNon Current Other Assets
Equity Investments with readily determinable value$451(57)59453453
Equity Investments without readily determinable value$773(26)76823823
(1)Recorded in Other (income)/expense, net
(2)Other includes impact of currency

Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.
The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.
The following three levels of inputs are used to measure fair value:
Level 1 — Quoted prices in active markets for identical assets and liabilities.
Level 2 — Significant other observable inputs.
Level 3 — Significant unobservable inputs.
The Company’s significant financial assets and liabilities measured at fair value as of June 29, 2025 and December 29, 2024 were as follows:
 June 29, 2025December 29, 2024
(Dollars in Millions)Level 1Level 2Level 3Total
Total(1)
Derivatives designated as hedging instruments:     
Assets:     
Forward foreign exchange contracts $—1,006—1,006660
Interest rate contracts(2)
—431—4311,484
Total —1,437—1,4372,144
Liabilities:     
Forward foreign exchange contracts —774—774794
Interest rate contracts(2)
—6,234—6,2343,753
Total —7,008—7,0084,547
Derivatives not designated as hedging instruments:     
Assets:     
Forward foreign exchange contracts —57—5750
Liabilities:     
Forward foreign exchange contracts —72—7217
Other Investments:
Equity investments(3)
453——453451
Debt securities(4)
—2,094—2,0947,216
Other Liabilities:
Contingent consideration(5)
$——1,1571,1571,217
Gross to Net Derivative ReconciliationJune 29, 2025December 29, 2024
(Dollars in Millions)
Total Gross Assets$1,4942,194
Credit Support Agreement (CSA)(1,471)(2,172)
Total Net Asset2322
Total Gross Liabilities7,0804,564
Credit Support Agreement (CSA)(6,666)(4,412)
Total Net Liabilities$414152
Summarized information about changes in liabilities for contingent consideration for the fiscal second quarters ended June 29, 2025 and June 30, 2024 is as follows:
June 29, 2025June 30, 2024
(Dollars in Millions)
Beginning Balance$1,2171,092
Changes in estimated fair value(6)
(60)44
Additions—112
Payments——
Ending Balance$1,1571,248
(1)2024 assets and liabilities are all classified as Level 2 with the exception of equity investments of $451 million, which are classified as Level 1 and contingent consideration of $1,217 million, classified as Level 3.
(2)Includes cross currency interest rate swaps and interest rate swaps.
(3)Classified as non-current other assets.
(4)Classified within cash equivalents and current marketable securities.
(5)Includes $1,107 million and $1,217 million classified as non-current other liabilities as of June 29, 2025 and December 29, 2024, respectively. Includes $50 million classified as current liabilities as of June 29, 2025.
(6)Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense.
The Company's cash, cash equivalents and current marketable securities as of June 29, 2025 comprised:
(Dollars in Millions)
Carrying
Amount
Unrealized Gain
Estimated
Fair Value
Cash & Cash
Equivalents
Current
Marketable
Securities
Cash$3,246—3,2463,246—
U.S. reverse repurchase agreements8,040—8,0408,040—
Money market funds4,637—4,6374,637—
Time deposits(1)
863—863863—
   Subtotal 16,786—16,78616,786—
U.S. Gov’t securities1,673—1,6731,65914
Other sovereign securities193—1939499
Corporate debt securities228—22838190
   Subtotal available for sale debt(2)
$2,094—2,0941,791303
Total cash, cash equivalents and current marketable securities$18,880—18,88018,577303
(1)Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings.
(2)Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
As of the fiscal year ended December 29, 2024, the carrying amount of cash, cash equivalents and current marketable securities was approximately the same as the estimated fair value.
Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.
The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as current marketable securities.
The contractual maturities of the available for sale securities as of June 29, 2025 are as follows:
(Dollars in Millions)Cost BasisFair Value
Due within one year$2,0752,075
Due after one year through five years1919
Due after five years through ten years——
Total debt securities$2,0942,094
Financial instruments not measured at fair value
The following financial liabilities are held at carrying amount on the consolidated balance sheet as of June 29, 2025:
(Dollars in Millions)
Carrying
Amount
Estimated
Fair Value
Financial Liabilities  
Current Debt$11,52611,495
Non-Current Debt  
2.95% Notes due 2027
950984
0.95% Notes due 2027
1,4781,410
4.50% Notes due 2027(1)
749757
2.90% Notes due 2028
1,4981,460
1.150% Notes due 2028 (750MM Euro 1.1704)
881843
4.55% Notes due 2028(1)
748762
4.80% Notes due 2029
1,1461,181
6.95% Notes due 2029
299334
2.70% Notes due 2029 (600MM Euro 1.1704)(1)
706708
1.30% Notes due 2030
1,6761,521
4.70% Notes due 2030(1)
9951,022
4.90% Notes due 2031
1,1461,189
3.20% Notes due 2032 (700MM Euro 1.1704)
821834
4.85% Notes due 2032(1)
1,2421,281
4.95% Notes due 2033
499517
4.375% Notes due 2033
853847
3.050% Notes due 2033 ( 700MM Euro 1.1704)(1)
822822
4.95% Notes due 2034

847880
1.650% Notes due 2035 (1.5B Euro 1.1704)
1,7561,528
5.00% Notes due 2035(1)
1,2441,282
3.35% Notes due 2036 (800MM Euro 1.1704)

937939
3.587% Notes due 2036
905902
5.95% Notes due 2037
9941,103
3.625% Notes due 2037
1,3961,334
3.350% Notes due 2037 (1.0B Euro 1.1704)(1)
1,1751,160
3.40% Notes due 2038
993857
5.85% Notes due 2038
697761
4.50% Notes due 2040
542523
2.10% Notes due 2040
885684
4.85% Notes due 2041
298291
4.50% Notes due 2043
496459
3.55% Notes due 2044 (1.0B Euro 1.1704)
1,1031,135
3.60% Notes due 2045 (700MM Euro 1.1704)(1)
819792
3.73% Notes due 2046
1,9791,592
3.75% Notes due 2047
863798
3.50% Notes due 2048
744567
2.25% Notes due 2050
851580
5.25% Notes due 2054

843837
3.70% Notes due 2055 (1.0B Euro 1.1704)(1)
1,1721,118
2.45% Notes due 2060
1,102694
Other8588
Total Non-Current Debt$39,23537,376
(1) In the fiscal first quarter of 2025, the Company issued senior unsecured notes for approximately $9.2 billion. The net proceeds from this offering were used to fund the Intra-Cellular Therapies, Inc. acquisition which closed on April 2, 2025, and for general corporate purposes.
The weighted average effective interest rate on non-current debt is 3.57%.
The excess of the carrying value over the estimated fair value of debt was $2.0 billion at December 29, 2024.
Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.
The current debt balance as of June 29, 2025, includes $8.5 billion of commercial paper which has a weighted average interest rate of 4.28% and a weighted average maturity of approximately two months.
v3.25.2
Income Taxes
 6 Months Ended
Jun. 29, 2025
Income Tax Disclosure [Abstract]  
Income Taxes Income taxes
The worldwide effective income tax rates for the fiscal six months of 2025 and 2024 were 17.8% and 16.1%, respectively.
The increase in the worldwide effective tax rate is primarily due to more income in higher tax jurisdictions, specifically in the U.S. In the fiscal six months of 2025 the Company reversed previously accrued reserves of approximately $7.0 billion for the Talc settlement proposal versus a charge of $3.0 billion recorded in the fiscal six months of 2024 for the Talc settlement proposal. Both were recorded at an effective rate for U.S. federal and state tax of approximately 22% (for further information see Note 11 to the Consolidated Financial Statements). Additionally in the fiscal six months of 2025, the effective tax rate benefited primarily from changes in uncertain international tax positions due to expiration of statute of limitations.
Subsequent to the end of the fiscal second quarter, on July 4, 2025, the United States enacted into law new tax legislation, the One Big Beautiful Bill Act, (OBBBA). The OBBBA includes provisions modifying the corporate income tax code, including the immediate expensing of domestic research and development expenditures for tax purposes, 100% bonus depreciation for qualified assets, and an increase in the statutory tax rate on foreign earnings from 10.5% to 12.6% (effective in the fiscal year 2026). The law also renamed the provision for taxes on foreign earnings from Global Intangible Low-Taxed Income (GILTI) to Net Controlled Foreign Corporation (CFC) Tested Income (NCTI). The Company has elected to account for GILTI, now NCTI, under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as NCTI is incurred in future periods. As a result, the Company will remeasure its deferred tax balances related to NCTI for the changes in the tax rate and will record an adjustment to this balance in the fiscal third quarter. The Company is still assessing this impact but is estimating this one-time re-measurement cost to be approximately $1.0 billion.
As of June 29, 2025, the Company had approximately $2.2 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the Internal Revenue Service has completed its audit for the tax years through 2016 and the audit for tax years 2017 through 2020 is ongoing.
In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2013. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States.
v3.25.2
Pensions and Other Benefit Plans
 6 Months Ended
Jun. 29, 2025
Retirement Benefits [Abstract]  
Pensions and Other Benefit Plans Pensions and other benefit plans
Components of net periodic benefit cost
Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans include the following components:
Fiscal Second Quarter EndedFiscal Six Months Ended
 Retirement PlansOther Benefit PlansRetirement PlansOther Benefit Plans
(Dollars in Millions)June 29, 2025June 30, 2024June 29, 2025June 30, 2024June 29, 2025June 30, 2024June 29, 2025June 30, 2024
Service cost$2192227269433446144138
Interest cost3563515352707703107104
Expected return on plan assets(599)(639)(1)(1)(1,186)(1,281)(3)(3)
Amortization of prior service cost/(credit)
(46)(46)(1)(1)(92)(92)(1)(1)
Recognized actuarial (gains)/losses85441513168873126
Curtailments and settlements—(8)———(8)——
Special termination benefits1———1———
Net periodic benefit cost/(credit)$16(76)13813231(145)278264
The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.
Company contributions
For the fiscal six months ended June 29, 2025, the Company contributed $69 million and $8 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.
v3.25.2
Accumulated Other Comprehensive Income
 6 Months Ended
Jun. 29, 2025
Equity [Abstract]  
Accumulated Other Comprehensive Income Accumulated other comprehensive income
Components of other comprehensive income/(loss) consist of the following:
(Dollars in Millions)
Foreign
Currency
Translation
Gain/
(Loss) On
Securities
Employee
Benefit
Plans
Gain/
(Loss) On
Derivatives
& Hedges
Total
Accumulated
Other
Comprehensive
Income/(Loss)
December 29, 2024$(8,441)1(1,551)(1,750)(11,741)
Net change(3,739)(1)851,091(2,564)
June 29, 2025(12,180)0(1,466)(659)(14,305)
Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income.
Details on reclassifications out of Accumulated Other Comprehensive Income:
Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.
Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.
Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.
v3.25.2
Earnings Per Share
 6 Months Ended
Jun. 29, 2025
Earnings Per Share [Abstract]  
Earnings Per Share Earnings per share
The following is a reconciliation of basic net earnings per share to diluted net earnings per share:
 Fiscal Second Quarter EndedFiscal Six Months Ended
(Shares in Millions)June 29, 2025June 30, 2024June 29, 2025June 30, 2024
Basic net earnings per share$2.301.956.873.30
Average shares outstanding — basic2,406.32,406.82,406.72,407.5
Potential shares exercisable under stock option plans64.662.667.079.3
Less: shares which could be repurchased under treasury stock method(51.8)(47.4)(50.4)(58.3)
Average shares outstanding — diluted2,419.12,422.02,423.32,428.5
Diluted net earnings per share$2.291.936.823.27
(Shares in Millions)
The diluted net earnings per share calculation excluded the following number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Company’s stock. 66.372.263.353.8
v3.25.2
Segments of Business and Geographic Areas
 6 Months Ended
Jun. 29, 2025
Segment Reporting [Abstract]  
Segments of Business and Geographic Areas Segments of business and geographic areas
The Company is organized into two business segments: Innovative Medicine and MedTech.
The Company’s chief operating decision maker (CODM) is the Chief Executive Officer (Principal Executive Officer). For the Innovative Medicine and MedTech segments, the CODM uses segment income before tax to allocate resources (including employees, financial, and capital resources) for each segment predominantly in the annual forecasting process. The CODM considers planning-to-actual variances on a quarterly basis to assess performance and make decisions about allocating resources to the segments.
Sales by segment of business
 Fiscal Second Quarter EndedFiscal Six Months Ended
(Dollars in Millions)June 29,
2025		June 30,
2024		Percent
Change		June 29,
2025		June 30,
2024
Percent
Change
INNOVATIVE MEDICINE
Oncology
U.S.
$3,3852,63628.4 %$6,3985,01927.5 %
International
2,9282,45519.3 5,5924,88514.5 
Worldwide
6,3125,09024.0 11,9909,90421.1 
CARVYKTI
U.S.
358167*676307*
International
8120*13236*
Worldwide
439186*808343*
DARZALEX
U.S.
2,0171,64123.0 3,8463,10523.9 
International
1,5211,23723.0 2,9302,46518.9 
Worldwide
3,5392,87823.0 6,7765,57021.7 
ERLEADA
U.S.
37831818.6 67060311.0 
International
53041827.0 1,00982222.9 
Worldwide
90873623.4 1,6791,42517.8 
IMBRUVICA
U.S.
239246(2.7)474511(7.3)
International
496525(5.4)9701,043(6.9)
Worldwide
735770(4.5)1,4441,554(7.0)
RYBREVANT/ LAZCLUZE(1)
U.S.
13952*25288*
International
4117*6928*
Worldwide
17969*320116*
TALVEY
U.S.
825938.0 15010936.7 
International
249*4217*
Worldwide
1066955.0 19212752.0 
TECVAYLI
U.S.
1141048.2 2192056.6 
International
523074.8 986356.0 
Worldwide
16613523.1 31726818.2 
 Fiscal Second Quarter EndedFiscal Six Months Ended
(Dollars in Millions)June 29,
2025		June 30,
2024		Percent
Change		June 29,
2025		June 30,
2024
Percent
Change
ZYTIGA / abiraterone acetate
U.S.
611(38.9)1320(31.9)
International
139154(9.8)257326(21.1)
Worldwide
145165(11.6)270346(21.7)
OTHER ONCOLOGY
U.S.
503736.9 977039.8 
International
4245(8.7)8486(2.5)
Worldwide
938311.7 18215616.4 
Immunology
U.S.
2,5052,978(15.9)4,7015,431(13.4)
International
1,4891,744(14.6)2,9993,538(15.2)
Worldwide
3,9934,722(15.4)7,7008,969(14.1)
REMICADE
U.S.
28323122.5 59749720.1 
U.S. Exports
3435(2.6)4462(28.7)
International
1381278.6 2812684.8 
Worldwide
45539315.9 92282711.5 
SIMPONI / SIMPONI ARIA
U.S.
30526714.0 59752114.4 
International
38727043.1 75356932.2 
Worldwide
69053728.6 1,3491,09123.7 
STELARA
U.S.
1,0781,855(41.9)2,0593,251(36.7)
International
5751,030(44.2)1,2192,085(41.5)
Worldwide
1,6532,885(42.7)3,2785,336(38.6)
TREMFYA
U.S.
79658935.2 1,3951,09827.1 
International
39131723.2 74761621.2 
Worldwide
1,18690631.0 2,1421,71425.0 
OTHER IMMUNOLOGY
U.S.
82*92*
International
00—00—
Worldwide
82*92*
Neuroscience
U.S.
1,3771,10224.9 2,3452,1568.7 
International
674679(0.8)1,3531,428(5.2)
Worldwide
2,0511,78215.1 3,6983,5853.2 
CAPLYTA(2)
U.S.
211—*211—*
International
——— ——— 
Worldwide
211—*211—*
 Fiscal Second Quarter EndedFiscal Six Months Ended
(Dollars in Millions)June 29,
2025		June 30,
2024		Percent
Change		June 29,
2025		June 30,
2024
Percent
Change
CONCERTA / methylphenidate
U.S.
2434(27.7)6275(16.6)
International
1391297.5 249265(6.0)
Worldwide
1641630.2 312340(8.3)
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
U.S.
732784(6.7)1,3571,549(12.4)
International
260269(3.5)537561(4.2)
Worldwide
9921,054(5.9)1,8952,110(10.2)
SPRAVATO
U.S.
36622661.1 64241753.7 
International
504412.8 937818.1 
Worldwide
41427153.3 73449648.1 
OTHER NEUROSCIENCE
U.S.
4557(23.5)73115(37.0)
International
226237(4.7)474524(9.5)
Worldwide
270294(8.4)547639(14.4)
Pulmonary Hypertension
U.S.
7997437.6 1,5431,5092.3 
International
3142965.8 5955792.6 
Worldwide
1,1131,0397.1 2,1382,0882.4 
OPSUMIT/OPSYNVI
U.S.4033766.9 7667324.6 
International1801715.4 339340(0.3)
Worldwide5825486.4 1,1041,0723.0 
UPTRAVI
U.S.3823499.4 7477410.8 
International947622.4 18015217.9 
Worldwide 47642611.7 9278943.7 
OTHER PULMONARY HYPERTENSION
U.S.
1617(12.4)3135(12.6)
International4049(18.5)7788(12.4)
Worldwide 5567(16.9)107123(12.5)
Infectious Diseases
U.S.
320334(4.3)635658(3.6)
International
484631(23.4)9711,128(13.9)
Worldwide
803965(16.8)1,6051,786(10.1)
EDURANT / rilpivirine
U.S.
68(25.4)1416(13.6)
International
35428823.0 70460316.7 
Worldwide
36029721.6 71862015.9 
 Fiscal Second Quarter EndedFiscal Six Months Ended
(Dollars in Millions)June 29,
2025		June 30,
2024		Percent
Change		June 29,
2025		June 30,
2024
Percent
Change
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
U.S.
312321(3.0)617635(2.9)
International
85117(27.0)183221(17.2)
Worldwide
396438(9.4)799856(6.6)
OTHER INFECTIOUS DISEASES
U.S.
25(51.8)47(37.4)
International
45227(80.5)84304(72.5)
Worldwide
47233(79.8)88311(71.7)
Cardiovascular / Metabolism / Other
U.S.7767178.2 1,6311,34821.0 
International154176(12.3)312373(16.2)
Worldwide9308924.2 1,9431,72112.9 
XARELTO
U.S.6215875.6 1,3111,10518.6 
International——— ——— 
Worldwide6215875.6 1,3111,10518.6 
OTHER
U.S.15512920.0 32024331.6 
International154176(12.3)312373(16.2)
Worldwide3093051.4 6326162.7 
TOTAL INNOVATIVE MEDICINE  
U.S.9,1618,5107.6 17,25316,1227.0 
International6,0415,9801.0 11,82211,930(0.9)
Worldwide15,20214,4904.9 29,07528,0523.6 
MEDTECH
Cardiovascular
U.S.1,3641,11921.9 2,6252,14422.4 
International94875325.9 1,7901,53416.7 
Worldwide2,3131,87323.5 4,4163,67920.0 
ELECTROPHYSIOLOGY
U.S.7417055.1 1,4251,3972.0 
International72861817.8 1,3661,2707.6 
Worldwide1,4681,32311.0 2,7912,6674.7 
ABIOMED
U.S.36030916.6 69961214.2 
International897225.0 17013922.4 
Worldwide44837918.2 86875015.7 
SHOCKWAVE(3)
U.S.23377*43977*
International580*1100*
Worldwide29277*55077*
 Fiscal Second Quarter EndedFiscal Six Months Ended
(Dollars in Millions)June 29,
2025		June 30,
2024		Percent
Change		June 29,
2025		June 30,
2024
Percent
Change
OTHER CARDIOVASCULAR
U.S.31295.4 63596.3 
International726413.4 14412614.2 
Worldwide1049310.8 20718511.7 
Orthopaedics
U.S.1,4201,422(0.2)2,8042,870(2.3)
International885890(0.5)1,7421,782(2.2)
Worldwide2,3052,312(0.3)4,5464,652(2.3)
HIPS
U.S.2712652.1 534535(0.2)
International150152(1.0)296304(2.5)
Worldwide4214171.0 830839(1.1)
KNEES
U.S.226230(1.9)457472(3.1)
International1641630.0 322323(0.5)
Worldwide389394(1.1)778795(2.0)
TRAUMA
U.S.5014980.7 1,0031,0020.1 
International2672602.2 5375212.9 
Worldwide7687591.2 1,5401,5241.1 
SPINE, SPORTS & OTHER
U.S.422430(1.7)810862(6.0)
International305314(2.7)588634(7.2)
Worldwide727743(2.1)1,3981,495(6.5)
Surgery
U.S.1,0439954.8 2,0451,9823.2 
International1,5121,4931.3 2,9062,922(0.5)
Worldwide2,5552,4882.7 4,9514,9041.0 
ADVANCED
U.S.4774662.2 9349122.4 
International6876751.9 1,3031,316(1.0)
Worldwide1,1641,1412.0 2,2372,2280.4 
GENERAL
U.S.5675287.2 1,1111,0703.8 
International8258180.9 1,6031,606(0.1)
Worldwide1,3911,3463.3 2,7142,6761.4
Vision
U.S.5575236.5 1,1231,0704.9 
International8137636.5 1,5261,4733.6 
Worldwide1,3691,2856.5 2,6482,5434.1 
 Fiscal Second Quarter EndedFiscal Six Months Ended
(Dollars in Millions)June 29,
2025		June 30,
2024		Percent
Change		June 29,
2025		June 30,
2024
Percent
Change
CONTACT LENSES / OTHER
U.S.4294094.8 8818473.9 
International5365095.4 1,0039812.3 
Worldwide9659185.1 1,8841,8283.1 
SURGICAL
U.S.12811312.6 2422238.5 
International2772548.8 5234926.2 
Worldwide4033679.9 7647156.9 
TOTAL MEDTECH    
U.S.4,3834,0598.0 8,5968,0676.6 
International4,1583,8986.7 7,9657,7113.3 
Worldwide8,5417,9577.3 16,56115,7785.0 
WORLDWIDE      
U.S.13,54412,5697.8 25,84924,1896.9 
International10,1999,8783.2 19,78719,6410.7 
Worldwide$23,74322,4475.8 %$45,63643,8304.1 %
*    Percentage greater than 100% or not meaningful
(1) Includes the sales of RYBREVANT and RYBREVANT + LAZCLUZE
(2) Acquired with the Intra-Cellular Therapies acquisition on April 2, 2025
(3) Acquired on May 31, 2024
Segment income before tax
 Fiscal Second Quarter Ended
(Dollars in Millions)June 29,
2025		June 30,
2024
Innovative Medicine(1)
MedTech(2)
Total
Innovative Medicine(1)
MedTech(2)
Total
Sales to customers$15,2028,54114,4907,957
Cost of products sold3,9783,6383,6033,248
Selling, marketing and administrative2,7892,8622,6652,671
Research and development expense2,8696472,722718
Other segment items (3)
1419041231
Segment income before tax$5,5521,2046,7565,4591,0896,548
(Income)/Expense not allocated to segments (4)
265800
Earnings before provision for taxes on income$6,491$5,748
Fiscal Six Months Ended
Sales to customers$29,07516,56128,05215,778
Cost of products sold7,9986,9646,9736,368
Selling, marketing and administrative5,0505,5185,1035,253
Research and development expense5,4171,3245,6181,364
Other segment items (3)
(152)130(70)184
Segment income before tax$10,7622,62513,38710,4282,60913,037
(Income)/Expense not allocated to segments (4)
(6,735)3,575
Earnings before provision for taxes on income$20,122$9,462
(1) Innovative Medicine includes:
•Intangible amortization expense of $0.8 billion and $0.7 billion in the fiscal second quarter of 2025 and 2024, respectively.
Intangible amortization expense of $1.4 billion in both the fiscal six months of 2025 and 2024.
•Acquisition and integration related expense of $0.2 billion in both the fiscal second quarter of 2025 and fiscal six months of 2025, primarily related to the Intra-Cellular acquisition.
•An In-process research and development impairment of $0.2 billion in the fiscal second quarter and fiscal six months of 2024 associated with the M710 (biosimilar) asset acquired from Momenta in 2020.
•Restructuring income of $0.1 billion in the fiscal second quarter of 2024 and a restructuring related charge of $0.1 billion in the fiscal six months of 2024.
(2)    MedTech includes:
•Intangible amortization expense of $0.5 billion and $0.4 billion in the fiscal second quarter of 2025 and 2024, respectively.
Intangible amortization expense of $1.0 billion and $0.8 billion in the fiscal six months of 2025 and 2024, respectively.
•Acquisition, integration and divestiture related net expense of $0.1 billion in the fiscal six months of 2025. Acquisition and integration related expense of $0.4 billion and $0.5 billion, in the fiscal second quarter and fiscal six months of 2024, respectively, primarily driven by the Abiomed and Shockwave acquisitions.
•A restructuring related charge of $0.1 billion in both the fiscal second quarter and fiscal six months of 2025 and 2024. Refer to Note 12 for additional details.
(3)    Other segment expenses for each reportable segment include charges related to other income and expense, restructuring activities and impairment charges related to in-process research and development.
(4) Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal six months of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal second quarter and fiscal six months of 2024 includes charges for talc matters of $0.3 billion and $3.0 billion, respectively. For additional details related to talc refer to Note 11 to the Consolidated Financial Statements. The fiscal second quarter and six months of 2024 includes a loss of approximately $0.4 billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock.
Identifiable Assets
(Dollars in Millions)June 29, 2025December 29, 2024
Innovative Medicine$75,48757,070
MedTech86,74584,322
Total162,232141,392
General corporate (1)
31,15738,712
Worldwide total$193,389180,104
(1)General corporate includes cash, cash equivalents, marketable securities and other corporate assets.
Additions to Property,
Plant & Equipment		Depreciation and
Amortization
(Dollars in Millions)June 29, 2025June 30, 2024June 29, 2025June 30, 2024
Innovative Medicine$687553$1,9251,861
MedTech1,0711,0741,6781,552
Segments total1,7581,6273,6033,413
General corporate80156112184
Worldwide total$1,8381,783$3,7153,597

Sales by geographic area
 Fiscal Second Quarter EndedFiscal Six Months Ended
(Dollars in Millions)June 29, 2025June 30, 2024Percent
Change		June 29, 2025June 30, 2024Percent Change
United States$13,54412,5697.8 %$25,84924,1896.9 %
Europe5,3875,2143.3 10,49710,3771.1 
Western Hemisphere, excluding U.S.1,2061,212(0.5)2,3732,406(1.3)
Asia-Pacific, Africa3,6063,4524.4 6,9176,8580.9 
Total$23,74322,4475.8 %$45,63643,8304.1 %
v3.25.2
Acquisitions and Divestitures
 6 Months Ended
Jun. 29, 2025
Business Combination [Abstract]  
Acquisitions and Divestitures Acquisitions and divestitures
Business combinations
2025 Transactions
On April 2, 2025, the Company completed the acquisition of Intra-Cellular Therapies, Inc. (Intra-Cellular), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders. This acquisition advances the Company’s industry-leading portfolio in mental health with the addition of CAPLYTA (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive therapy and monotherapy and is also approved for the treatment of schizophrenia in adults. Further, an sNDA has been submitted to the U.S. FDA for CAPLYTA as adjunctive treatment for major depressive disorder. This acquisition also includes a promising clinical-stage pipeline with best-in-class potential in generalized anxiety disorder and Alzheimer’s disease-related psychosis and agitation.

The Company acquired all the outstanding shares of Intra-Cellular’s common stock for $132.00 per share in an all-cash merger transaction for total consideration transferred of $14.5 billion. The acquisition was accounted for as a business combination and the results of operations and goodwill are included in the Innovative Medicine segment as of the acquisition date. In addition, acquisition-related costs before tax incurred during the fiscal six months of 2025 were $0.2 billion, of which $0.1 billion related to post-closing compensation expense due to the acceleration of equity awards and were recorded to Other (income) expense, net.

The following table summarizes the preliminary fair value of assets acquired and liabilities assumed as of the acquisition date and is based on the best estimate of management, which is subject to change within the measurement period.

(Dollars in Billions)April 2, 2025
Assets acquired:
Cash and cash equivalents $0.2
Marketable securities0.6
Other current & non-current assets0.3
Amortizable intangible asset (1)
5.2
Acquired in-process research and development (1)
8.3
Goodwill (2)
2.9
Total assets acquired$17.5
Liabilities assumed:
Deferred taxes$2.8
Other current & non-current liabilities0.2
Total liabilities assumed$3.0
Total assets acquired and liabilities assumed$14.5
(1) The estimated fair values of the intangible assets acquired were determined using the multi-period excess earnings method. The amortizable intangible asset relates to the currently marketed product, Caplyta, which has an estimated useful life of 8 years. The acquired in-process research and development includes two assets, one related to certain unapproved indications of lumateperone and another related to a compound being studied to treat psychosis and agitation in patients with Alzheimer’s disease and generalized anxiety disorder. The fair value of the in-process research and development assets were calculated assuming a discount rate of 11.5% and 12.5%, respectively. Additionally, the cash flow projections assumed a probability of success factor of 95% and approximately 34-50% (depending on indication being studied), respectively.

(2) Goodwill is primarily attributable to intangible assets that did not qualify for separate recognition and future projects or products currently unidentified. Goodwill is not expected to be deductible for tax purposes.

2024 Transactions
On June 20, 2024, the Company completed the acquisition of Proteologix, Inc., a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases, in an all-cash merger transaction for total consideration of $0.8 billion net of cash acquired, with potential for an additional milestone payment. The results of operations were included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $1.2 billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&D, for $0.9 billion, goodwill for $0.3 billion, and liabilities
assumed of $0.3 billion, including $0.1 billion of contingent consideration. The goodwill is not deductible for tax purposes. Acquisition related costs before tax for the fiscal six months of 2025 are not material.

On May 31, 2024, the Company acquired all the outstanding shares of Shockwave Medical Inc. (SWAV), a leading, first-to-market provider of innovative intravascular lithotripsy (IVL) technology for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD), in an all-cash merger transaction for total consideration of $12.6 billion, ($11.5 billion, net of cash acquired). The results of operations were included in the MedTech segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $14.4 billion primarily amortizable intangible assets of $5.3 billion, purchased IPR&D of $0.6 billion, goodwill for $7.6 billion, $0.5 billion of inventory and $0.4 billion of other assets, and liabilities assumed of $2.9 billion. The goodwill is not deductible for tax purposes. Acquisition related costs before tax for the fiscal six months of 2025 are not material.

On March 7, 2024, the Company completed the acquisition of Ambrx Biopharma, Inc., (Ambrx), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total consideration of approximately $1.8 billion net of cash acquired. The results of operations were included in the Innovative Medicine segment as of the acquisition date. The fair value of the acquisition was allocated to assets acquired of $2.3 billion, primarily non-amortizable intangible assets, inclusive of purchased IPR&D, for $1.9 billion, goodwill for $0.3 billion and liabilities assumed of $0.5 billion. The goodwill is not deductible for tax purposes. Acquisition related costs before tax for the fiscal six months of 2025 are not material.

Asset acquisitions
There were no material asset acquisitions in the fiscal six months of 2025 or 2024.
Divestitures
There were no material divestitures in the fiscal six months of 2025.

In the fiscal second quarter of 2024, the Company completed the divestiture of Acclarent resulting in approximately $0.3 billion in proceeds. In the fiscal first quarter of 2024, the Company completed the divestiture of Ponvory outside of the U.S. resulting in approximately $0.2 billion in proceeds.
v3.25.2
Legal Proceedings
 6 Months Ended
Jun. 29, 2025
Commitments and Contingencies Disclosure [Abstract]  
Legal Proceedings Legal proceedings
Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.
The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of June 29, 2025, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.
In the Company’s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company’s balance sheet, is not expected to have a material adverse effect on the Company’s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company’s results of operations and cash flows for that period.
Matters concerning talc
A significant number of personal injury claims alleging that talc causes cancer have been asserted against the Company and its affiliates arising out of the use of body powders containing talc, primarily JOHNSON’S Baby Powder.
In talc cases that have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7 billion in Ingham v. Johnson & Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $2.1 billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied, and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $2.5 billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company. The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company’s confidence in the safety of its talc products, in certain circumstances the Company has settled cases.
In an effort to expeditiously resolve the litigation for the overwhelming majority of claimants, beginning in October 2021, Johnson & Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring, through which Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor’s direct parent, Johnson & Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI’s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers’ compensation statute or act (the Talc-Related Liabilities).
Following the 2021 Corporate Restructuring, Debtor and the Company attempted to achieve a full and comprehensive resolution of the Talc-Related Liabilities. Debtor filed voluntary petitions for Bankruptcy pursuant to Chapter 11 of the Bankruptcy Code in October 2021 and again in April 2023; both petitions were dismissed.
In October 2023, the Company stated that it was pursuing the following four parallel and alternative pathways to achieve a comprehensive and final resolution of the talc claims: (i) the appeal of the LTL 2 dismissal decision; (ii) pursuing a consensual “prepackaged” bankruptcy case, as “strongly encouraged” by the Bankruptcy Court in its dismissal decision; (iii) aggressively litigating the talc claims in the tort system; and (iv) pursuing affirmative claims against experts for false and defamatory narratives
regarding the Company’s talc powder products. In December 2023, LTL changed its state of formation to Texas and its name to LLT Management LLC (LLT).
In May 2024, the Company commenced a three-month solicitation period of its proposed consensual “prepackaged” Chapter 11 bankruptcy plan (the Proposed Plan) for the comprehensive and final resolution of all current and future claims related to cosmetic talc in the United States, excluding claims related to mesothelioma or State consumer protection claims, in exchange for the payment by the Company of present value of approximately $6.475 billion payable over 25 years (nominal value of approximately $8.0 billion, discounted at a rate of 4.4%). The claims encompassed by the Proposed Plan constituted 99.75% of then-pending lawsuits against the Company relating to its talc powder products.
In August 2024, LLT engaged in a restructuring that resulted in the creation of three new Texas limited liability companies: (a) Red River Talc, LLC (Red River); (b) Pecos River Talc LLC (Pecos River); and (3) New Holdco (Texas) LLC. As a result of this restructuring, all claims related to ovarian and other gynecological cancers were separated and allocated to Red River, and mesothelioma, governmental unit and certain other claims were allocated to Pecos River.
While the Company had resolved 95% of the mesothelioma lawsuits filed to date as of August 2024, cases continue to be filed. Trials have commenced in various state courts.
In September 2024, while reiterating the Company's continued confidence in the safety of its talc products, Red River filed a voluntary petition with the United States Bankruptcy Court for the Southern District of Texas, seeking relief under Chapter 11 of the Bankruptcy Code (the Red River Bankruptcy Case), in furtherance of the Company's consensual "prepackaged" Proposed Plan. Shortly thereafter, as a consequence of this filing, the Company withdrew its appeal of the LTL 2 dismissal decision.
To account for the contemplated comprehensive resolution through the Proposed Plan, the Company recorded a cumulative incremental charge of approximately $5.0 billion during fiscal year 2024. As of the end of fiscal year 2024, the total present value of the reserve was approximately $11.6 billion (or nominal value of approximately $13.5 billion).
On March 31, 2025, the Texas Bankruptcy Court issued an order dismissing the case (the Texas dismissal) and, as a result, the Company reversed substantially all, or approximately $7 billion, from amounts previously reserved for the bankruptcy resolution. As of the second quarter 2025, the total present value of the reserve is approximately $4.0 billion, comprising previously executed settlement agreements, litigation defense and other costs. Approximately one-third of the reserve is recorded as a current liability.
After the Texas dismissal, the Company announced it would not appeal the decision and returned to the tort system to litigate the talc claims and defend the safety of its products. Courts have begun to hold scheduling conferences and the Company is preparing to start bellwether trials in consolidated proceedings in the California JCCP in November 2025 and in the New Jersey MCL in January 2026.
In February 2019, the Company’s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition for relief under Chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy) seeking indemnification from the Company and rights to joint insurance proceeds.
In February 2021, Cyprus Mines Corporation (Cyprus), which had owned certain Imerys talc mines, filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code in the Delaware Bankruptcy Court and filed its Disclosure Statement and Plan (the Cyprus Plan) also asserting claims for indemnity against the Company arising out of personal injury claims.
In July 2024, the Company, Imerys, and Cyprus and certain of their affiliates (including their parent entities), and the tort claimants' committees and future claimants' representatives appointed in the Imerys debtors' and Cyprus debtors' respective Chapter 11 cases entered into a global settlement agreement (the Imerys Settlement Agreement) to resolve the parties ongoing disputes, including disputes raised in the Imerys and Cyprus bankruptcies. In October 2024, the Delaware Bankruptcy Court entered an order approving the Imerys Settlement Agreement (the Settlement Order).
Certain insurers have appealed the Settlement Order and sought a stay of the order pending appeal, which the Delaware Bankruptcy Court denied in January 2025. The insurers then sought a stay of the order in the District Court for the District of Delaware, which also was denied. The insurers then appealed the denial of their request for a stay of the order to the Third Circuit Court of Appeals. The briefing of the Settlement Order appeal in the Delaware District Court was completed in April 2025, and the appeal is pending a decision from the Court. The briefing in the Third Circuit appeal of the denial of the stay order is ongoing.
In January 2025, Imerys and Cyprus each filed a certification of voting results, indicating that their respective Chapter 11 plans had been accepted by each voting class of talc claimants. A joint confirmation hearing for the plans began in April 2025 but was continued, at the request of Imerys and Cyprus, after issues arose relating to treatment of foreign claims under their respective Chapter 11 plans.
In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S Baby Powder, and that purchasers of the Company’s shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. In December 2023, the Court granted Plaintiff’s motion for class certification. In January 2024, Defendants filed a petition with the Third Circuit under Federal Rule of Civil Procedure 23(f) for permission to appeal the Court’s order granting class certification, and in February 2024, the Third Circuit granted Defendants' petition. In February 2024, fact discovery closed, the Court ordered the parties to mediate, and stayed the case pending mediation. In May 2024, the parties participated in an unsuccessful mediation. In June 2024, at the parties' request, the Court lifted the stay for certain limited discovery, but otherwise kept the stay in place pending a decision from the Third Circuit on the 23(f) petition. Briefing on the 23(f) petition was completed in September 2024, and in March 2025, the Third Circuit heard oral argument.
Matters concerning opioids
Beginning in 2014 and continuing to the present, the Company and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children born with Neonatal Abstinence Syndrome (NAS); hospitals; and health insurers/payors.
To date, the Company and JPI have litigated two of the cases to judgment and have prevailed in both, either at trial or on appeal.
In July 2021, the Company announced finalization of an agreement to settle the state and subdivision claims for up to $5.0 billion. Approximately 80% of the all-in settlement was paid by the end of fiscal second quarter 2025. A few government entities opted out of the settlement. In September 2024, the Company reached an agreement to resolve the hospital cases.
The Company and JPI continue to defend the cases brought by the remaining government entity litigants as well as the cases brought by private litigants. In total, there are under 27 remaining opioid cases against the Company and JPI in various state courts, 290 remaining cases in the Ohio multi-district litigation (MDL), and 2 additional cases in other federal courts.
In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate Janssen Inc., and many other industry members, in Canada. That action was certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada in January 2025. The defendants, including the Company, filed appeals from the certification order in late February 2025. Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. The proposed class action in Quebec on behalf of residents diagnosed with opioid use disorder was authorized to proceed against Janssen Inc. and other industry members in April 2024; and leave to appeal was denied in October 2024.
Starting in November 2019, a series of shareholder derivative complaints were filed against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches. As of September 2024, all the complaints had been dismissed, and all appeals exhausted.
Product liability
The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25, Contingencies. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.
The table below contains the most significant of these cases and provides the approximate number of plaintiffs in the United States with direct claims in pending lawsuits regarding injuries allegedly due to the relevant product or product category as of June 29, 2025
Product or product category
Number of plaintiffs
Body powders containing talc, primarily JOHNSON’S Baby Powder70,030
DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System40
PINNACLE Acetabular Cup System860
Pelvic meshes5,350
ETHICON PHYSIOMESH Flexible Composite Mesh120
ELMIRON920
The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. There may be additional claims that have not yet been filed.
MedTech
DePuy ASR XL Acetabular System and ASR Hip Resurfacing System
In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Ireland, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.
DePuy PINNACLE Acetabular Cup System
Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.
Ethicon Pelvic Mesh
Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicon’s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company’s accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon’s pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, and Ireland, and class actions in Israel, Australia, Canada and South Africa. The vast majority of these actions are now resolved. The Company has established accruals with respect to product liability litigation associated with Ethicon’s pelvic mesh products.
Ethicon Physiomesh
Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this
hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. Other than a small number of cases still pending in the MDL, all Physiomesh matters in the United States have been resolved or are undergoing formal review for purposes of settlement.
Claims have also been filed against Ethicon and the Company alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States.
Ethicon and the Company also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States.
In October 2022, an agreement in principle, subject to various conditions, was reached to settle the majority of the pending cases involving Proceed, Proceed Ventral Patch, Prolene Hernia System and related multi-layered mesh products, as well as a number of unfiled claims. All litigation activities in the two New Jersey MCLs are stayed pending effectuation of the proposed settlement. Future cases that are filed in the New Jersey MCLs will be subject to docket control orders requiring early expert reports and discovery requirements.
The Company has established accruals with respect to product liability litigation associated with Ethicon Physiomesh Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products.
Innovative Medicine
ELMIRON
Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey (MDL). In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. The Company continues to defend ELMIRON product liability lawsuits and continues to evaluate potential costs related to those claims. All U.S. based ELMIRON matters have been resolved or are undergoing formal review for purposes of settlement. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.
Intellectual property
Certain subsidiaries of the Company are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the scope and/or validity of patents that relate to various products and allegations that certain of the Company’s products infringe the intellectual property rights of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset.
Innovative Medicine - litigation against filers of abbreviated new drug applications (ANDAs)
The Company’s subsidiaries have brought lawsuits against generic companies that have filed ANDAs with the U.S. FDA (or similar lawsuits outside of the United States) seeking to market generic versions of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These lawsuits typically include allegations of non-
infringement and/or invalidity of patents listed in FDA’s publication “Approved Drug Products with Therapeutic Equivalence Evaluations” (commonly known as the Orange Book). In each of these lawsuits, the Company’s subsidiaries are seeking an order enjoining the defendant from marketing a generic version of a product before the expiration of the relevant patents (Orange Book Listed Patents). In the event the Company’s subsidiaries are not successful in an action, or any automatic statutory stay expires before the court rulings are obtained, the generic companies involved would have the ability, upon regulatory approval, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company’s subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents.
The Inter Partes Review (IPR) process with the United States Patent and Trademark Office (USPTO), created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits to challenge the applicable patents.
XARELTO
Beginning in March 2021, Janssen Pharmaceuticals, Inc., Bayer Pharma AG, Bayer AG and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddy’s Laboratories, Inc.; Dr. Reddy’s Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mankind Pharma Limited; Apotex Inc.; Apotex Corp.; Cipla Ltd.; Cipla USA Inc.; and InvaGen Pharmaceuticals, Inc. The following U.S. patents are included in one or more cases: 9,539,218 and 10,828,310.
U.S. Patent No. 10,828,310 was also under consideration by the USPTO in an IPR proceeding. In July 2023, the USPTO issued a final written decision finding the claims of the patent invalid. In September 2023, Bayer Pharma AG filed an appeal to the U.S. Court of Appeals for the Federal Circuit. Oral argument was heard in May 2025.
INVEGA SUSTENNA
Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; Accord Healthcare, Inc.; Qilu Pharmaceutical Co. Ltd.; and Qilu Pharma Inc. The following U.S. patent is included in one or more cases: 9,439,906. In October 2020, the district court issued a decision in the case against Teva Pharmaceuticals USA, Inc., finding that United States Patent No. 9,439,906 is not invalid. Teva previously stipulated to infringement. Teva appealed the decision, and, in April 2024, the United States Court of Appeals for the Federal Circuit vacated and remanded the case to the district court for further proceedings. In November 2024, the district court issued its decision on remand, finding that United States Patent No. 9,439,906 is not invalid. Teva appealed to the Court of Appeals for the Federal Circuit, and oral argument took place in April 2025. In July 2025, the Federal Circuit affirmed the district court ruling of no invalidity. The Mylan case was consolidated with the Teva case for purposes of appeal and the July ruling applies to Mylan. In February 2024, the district court issued a decision in the case against Tolmar Inc. finding that United States Patent No. 9,439,906 is not invalid. Tolmar previously stipulated to infringement. Tolmar has appealed the decision.
Beginning in February 2018, Janssen Inc. and Janssen Pharmaceutica NV initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the listed patent. The following entities are named defendants: Pharmascience Inc. and Apotex Inc. The following Canadian patent is included in one or more cases: 2,655,335. In June 2024, the Supreme Court dismissed the Apotex case. In September 2024, the Supreme Court granted Pharmascience's motion to appeal the Federal Court's decision that the 2,655,335 Patent is not invalid.
INVEGA TRINZA
Beginning in September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research & Development, LLC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA TRINZA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Mylan Laboratories Limited; Mylan Pharmaceuticals Inc.; and Mylan Institutional LLC. The following U.S. patent is included in one or more cases: 10,143,693. In May 2023, the District Court issued a decision finding that Mylan’s proposed generic product infringes the asserted patent and that the patent is not invalid. Mylan appealed the decision, and in March 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the district court's decision. In May 2025, Mylan filed a petition for panel
rehearing or rehearing en banc with the U.S. Court of Appeals for the Federal Circuit. In July 2025, the court denied Mylan's petition.
ERLEADA
In January 2025, Aragon Pharmaceuticals, Inc., Janssen Inc., (collectively, Janssen Inc.) and Sloan-Kettering Institute for Cancer Research (SKI) initiated Statements of Claims under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in response to Sandoz’s filing of an ANDS seeking approval to market a generic version of ERLEADA before the expiration of CA Patent Nos. 3,008,345 (the ’345 patent), 2,875,767 (the ’767 patent), 2,885,415 (the ’415 patent), and 3,128,331 (the ’331 patent). Janssen Inc. and SKI are seeking an order enjoining Sandoz from marketing a generic version of ERLEADA before the expiration of the relevant patents.
Beginning in April 2025, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., The Regents of the University of California, and Sloan-Kettering Institute for Cancer Research variously initiated patent infringement lawsuits in U.S. District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of ERLEADA before the expiration of certain Orange Book listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; Hetero Labs Limited Unit V; and Hetero USA, Inc. The following U.S. patents are included in one or more cases: 8,445,507; 8,802,689; 9,338,159; 9,987,261; 9,481,663; 9,884,054; RE49,353; 10,849,888; 10,702,508; and 11,963,952.
SPRAVATO
Beginning in May 2023, Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SPRAVATO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sandoz Inc.; Hikma Pharmaceuticals Inc. USA; Hikma Pharmaceuticals PLC; and Alkem Laboratories Ltd. The following U.S. patents are included in one or more cases: 10,869,844; 11,173,134; 11,311,500; and 11,446,260.
INVOKANA
Beginning in January 2024, Janssen Inc. and Mitsubishi Tanabe Pharma Corporation initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who filed ANDSs seeking approval to market generic versions of INVOKANA before expiration of the listed patents. The following entities are named defendants Jamp Pharma Corporation (Jamp) and Apotex Inc. (Apotex). The following Canadian patents are included in one or more cases 2,534,024 and 2,671,357. The Company entered into confidential settlement agreements with Jamp, in April 2025, and with Apotex, in July 2025.
CAPLYTA
Beginning in March 2024, Intra-Cellular Therapies, Inc. (Intra-Cellular) filed patent infringement lawsuits in the United States District Court for the District of New Jersey against generic manufactures who have filed ANDAs seeking approval to market generic versions of CAPLYTA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Alkem Laboratories Ltd., Dr. Reddy’s Laboratories Inc., Dr. Reddy’s Laboratories Ltd., Hetero USA, Inc., Hetero Labs Ltd. Unit-V, Hetero Labs Ltd., MSN Laboratories Private Ltd., Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Ltd. The following U.S. Patents are included in one or more cases: US RE 48,825; RE 48,839; 8,648,077; 9,168,258; 9,199,995; 9,616,061; 9,956,227; 10,117,867; 10,464,938; 10,960,009; 11,026,951; 11,753,419; 11,980,617; 12,070,459; 12,090,155; 12,122,792; and 12,128,043. In July 2025, Intra-Cellular, Hetero USA, Inc., Hetero Labs Ltd. Unit-V, and Hetero Labs Ltd. entered into a confidential settlement agreement.
MedTech
In March 2016, Abiomed, Inc. filed a declaratory judgment action against Maquet Cardiovascular LLC (Maquet) in the U.S. District Court for the District of Massachusetts seeking a declaration that certain Impella products do not infringe Maquet patents, including U.S. Patent Nos. 7,022,100 (’100 patent); 8,888,728; and 9,327,068. Maquet counterclaimed for infringement of those patents against Abiomed, Inc., Abiomed Europe GmbH, and Abiomed R&D, Inc. (collectively, Abiomed), and later added claims for infringement of U.S. Patent Nos. 9,545,468; 9,561,314; and 9,597,437. After claim construction, Maquet alleged infringement of only the ’100 patent. In September 2021, the court granted Abiomed’s motion for summary judgment of non-infringement of the ’100 patent, and in September 2023, the district court entered final judgment in favor of Abiomed on all patents-in-suit. Maquet appealed.
In November 2017, Maquet Cardiovascular LLC filed suit against Abiomed, Inc., Abiomed R&D, Inc., and Abiomed Europe GmbH (collectively, Abiomed) in the U.S. District Court for the District of Massachusetts, alleging that certain Impella products infringe U.S. Patent No. 9,789,238 (’238 patent). Maquet subsequently added U.S. Patent No. 10,238,783 (’783 patent). After claim construction, the court entered a stipulated judgment of non-infringement of both patents. Maquet appealed. On March 21, 2025,
the U.S. Court of Appeals for the Federal Circuit left undisturbed the judgment on non-infringement of the ’238 patent, vacated the judgment regarding the ’783 patent, and remanded the case to the District Court for further proceedings on the ’783 patent.

Government proceedings
Like other companies in the pharmaceutical and medical technologies industries, the Company and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.
MedTech
In July 2023, the DOJ issued Civil Investigative Demands to the Company, Johnson & Johnson Surgical Vision, Inc., and Johnson & Johnson Vision Care, Inc. (collectively, J&J Vision) in connection with a civil investigation under the False Claims Act relating to free or discounted intraocular lenses and equipment used in eye surgery, such as phacoemulsification and laser systems. J&J Vision has provided documents and information responsive to the Civil Investigative Demands and is continuing to cooperate with the DOJ regarding its inquiry.
Innovative Medicine
In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and trial commenced in May 2024. On June 13, 2024, a jury found no liability regarding the anti-kickback violations but found liability for a portion of the off-label promotion claims. The Company is pursuing post-trial briefing challenging the verdict on the off-label claims. On March 28, 2025, the Court granted in part and denied in part Janssen’s motions and the Company is appealing the verdict and judgments. The Company filed a notice of appeal with the Third Circuit on April 29, 2025. Briefing is ongoing.
In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway.
General litigation
The Company or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the Company’s agreement to implement remediation activities at designated hazardous waste sites or to reimburse the government or third parties for the costs they have incurred in performing remediation at such sites.
In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson & Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Court’s decision. In June 2023, defendants filed a petition for a writ of certiorari to the United States Supreme Court. In June 2024, the Supreme Court vacated the D.C. Circuit's decision and remanded the case to the D.C. Circuit. Oral argument was held in November 2024.
In February 2024, a putative class action was filed against the Company and the Pension & Benefits Committee of Johnson & Johnson (Committee) in United States District Court for the District of New Jersey. The complaint alleges that defendants breached fiduciary duties under the Employee Retirement Income Security Act (ERISA) by allegedly mismanaging the Company’s prescription-drug benefits program. The complaint seeks damages and other relief. In January 2025, the Court granted in part and
denied in part defendants’ motion to dismiss, with leave to replead. In March 2025, plaintiffs filed a second amended complaint. In April 2025, defendants filed a motion to dismiss plaintiffs' fiduciary duty claims.
MedTech
In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon’s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants’ motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial occurred in January 2024. In September 2024, the court found liability with respect to certain claims and no liability with respect to other claims. The Company has appealed the decision.
In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc (BWI) in the United States District Court for the Central District of California. The complaint alleges that certain of BWI's business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In May 2025, a jury returned its verdict in favor of Innovative Health. Innovative Health is seeking a permanent injunction. BWI intends to appeal once the judgment is final.
Innovative Medicine
In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc. and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In September 2024, the district court granted plaintiff's motion for class certification. Trial is scheduled for March 2026.
In December 2023, a putative class action lawsuit was filed against the Company and Janssen Biotech Inc. (collectively Janssen) in the United States District Court for the Eastern District of Virginia. The complaint alleges that Janssen violated federal and state antitrust laws and other state laws by delaying biosimilar competition with STELARA through Janssen's enforcement of patent rights covering STELARA. The complaint seeks damages and other relief. In February 2024, plaintiffs filed an amended complaint, which Janssen moved to dismiss in March 2024. In August 2024, the court granted in part and denied in part Janssen's motion to dismiss.
In December 2018, Janssen Biotech, Inc., Janssen Oncology, Inc., Janssen Research & Development, LLC and Johnson & Johnson (collectively, Janssen) were served with a qui tam complaint on behalf of the United States, certain states, and the District of Columbia. The complaint alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct sales and reimbursement programs. At this time, the federal and state governments have declined to intervene. In December 2021, the United States District Court for the District of New Jersey denied Janssen's motion to dismiss.
v3.25.2
Restructuring
 6 Months Ended
Jun. 29, 2025
Restructuring and Related Activities [Abstract]  
Restructuring Restructuring
In fiscal 2025, the company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. Restructuring expenses of $29 million were recorded in the fiscal second quarter of 2025. The estimated costs of the total program are between $0.9 billion - $1.0 billion and is expected to be completed over the next two years.
In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within its MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The pre-tax restructuring expense in the fiscal second quarter and fiscal six months of 2025 primarily included costs related to asset impairments as well as market and product exits. The pre-tax restructuring expense in the fiscal second quarter and fiscal six months of 2024 primarily included market and product exits. Total project costs of approximately $0.6 billion have been recorded since the restructuring was announced. The estimated costs of the total program are between $0.7 billion - $0.8 billion and is expected to be substantially completed by the end of fiscal year 2025.
The following table summarizes the restructuring expenses for 2025 and 2024:
(Pre-tax Dollars in Millions)Q2 2025Q2 2024Q2 YTD 2025Q2 YTD 2024
MedTech Segment Surgery franchise(1)
$29—29—
MedTech Segment Orthopaedics franchise(2)
505210579
Innovative Medicine Segment(3)
—(63)—81
Total Programs$79(11)134160
(1)Included in Restructuring on the Consolidated Statement of Earnings in the fiscal second quarter and fiscal six months of 2025.
(2)Included $35 million in Restructuring and $15 million in Cost of products sold on the Consolidated Statement of Earnings in the fiscal second quarter of 2025. Included $52 million in Restructuring, $23 million in Cost of products sold and $30 million in Other (Income)/Expense on the Consolidated Statement of Earnings in the fiscal six months of 2025. Included $50 million in Restructuring and $2 million in Cost of products sold on the Consolidated Statement of Earnings in the fiscal second quarter of 2024. Included $70 million in Restructuring and $9 million in Cost of products sold on the Consolidated Statement of Earnings in the fiscal six months of 2024.
(3)Included in Restructuring on the Consolidated Statement of Earnings. This program was completed in the fiscal fourth quarter of 2024.
Restructuring reserves as of June 29, 2025 and December 29, 2024 were insignificant.
v3.25.2
Pay vs Performance Disclosure - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 29, 2025
Jun. 30, 2024
Jun. 29, 2025
Jun. 30, 2024
Pay vs Performance Disclosure        
Net earnings $ 5,537 $ 4,686 $ 16,536 $ 7,941
v3.25.2
Insider Trading Arrangements
 3 Months Ended
Jun. 29, 2025
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.25.2
Summary of Significant Accounting Policies (Policies)
 6 Months Ended
Jun. 29, 2025
Accounting Policies [Abstract]  
New and Recently Adopted Accounting Standards
New accounting standards
The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2024.
Recently adopted accounting standards
There were no new material accounting standards adopted in the fiscal six months of 2025.
Recently issued accounting standards
There were no new material accounting standards issued in the fiscal six months of 2025.
Cash and Cash Equivalents
The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as current marketable securities.
v3.25.2
Inventories (Tables)
 6 Months Ended
Jun. 29, 2025
Inventory Disclosure [Abstract]  
Summary of Inventories
(Dollars in Millions)June 29, 2025December 29, 2024
Raw materials and supplies$2,3892,337
Goods in process3,9712,815
Finished goods7,0527,292
Total inventories$13,41212,444
v3.25.2
Intangible Assets and Goodwill (Tables)
 6 Months Ended
Jun. 29, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets and Goodwill
(Dollars in Millions)June 29, 2025December 29, 2024
Intangible assets with definite lives:  
Patents and trademarks — gross$53,27244,695
Less accumulated amortization(30,756)(26,124)
Patents and trademarks — net$22,51618,571
Customer relationships and other intangibles — gross21,91020,310
Less accumulated amortization(14,487)(13,544)
Customer relationships and other intangibles — net(1)
$7,4236,766
Intangible assets with indefinite lives:  
Purchased in-process research and development19,89612,281
Total intangible assets — net$49,83537,618
(1)The majority is comprised of customer relationships
Goodwill
Goodwill as of June 29, 2025 was allocated by segment of business as follows:
(Dollars in Millions)
Innovative
Medicine
MedTechTotal
Goodwill at December 29, 2024
$10,69233,50844,200
Goodwill, related to acquisitions2,876—2,876
Goodwill, related to divestitures—(29)(29)
Currency translation/Other7583121,070
Goodwill at June 29, 2025
$14,32633,79148,117
Intangible Asset Amortization Expense
The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:
(Dollars in Millions)
20252026202720282029
$4,5004,0003,4002,7002,600
v3.25.2
Fair Value Measurements (Tables)
 6 Months Ended
Jun. 29, 2025
Fair Value Disclosures [Abstract]  
Summary of Derivative Activity
The following table is a summary of the activity related to derivatives and hedges for the fiscal second quarters ended June 29, 2025 and June 30, 2024, net of tax:


June 29, 2025June 30, 2024
(Dollars in Millions)Sales
Cost of
Products
Sold
R&D
Expense
Interest
(Income)
Expense
Other
(Income)
Expense
Sales
Cost of
Products
Sold
R&D
Expense
Interest
(Income)
Expense
Other
(Income)
Expense
The effects of fair value, net investment and cash flow hedging:
Gain (Loss) on fair value hedging relationship:
Interest rate swaps contracts:
    Hedged items$———52————(53)—
    Derivatives designated as hedging instruments———(52)————53—
Gain (Loss) on net investment hedging relationship:
Cross currency interest rate swaps contracts:
   Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing———48————33—
   Amount of gain or (loss) recognized in AOCI———48————33—
Gain (Loss) on cash flow hedging relationship:
Forward foreign exchange contracts:
   Amount of gain or (loss) reclassified from AOCI into income 2(132)(16)—(3)(1)948—3
   Amount of gain or (loss) recognized in AOCI 11466(72)—(29)26611—1
Cross currency interest rate swaps contracts:
   Amount of gain or (loss) reclassified from AOCI into income———76————42—
   Amount of gain or (loss) recognized in AOCI$———108————(38)—
The following table is a summary of the activity related to derivatives and hedges for the fiscal six months ended June 29, 2025 and June 30, 2024, net of tax:


June 29, 2025June 30, 2024
(Dollars in Millions)SalesCost of Products SoldR&D ExpenseInterest (Income) ExpenseOther (Income) ExpenseSalesCost of Products SoldR&D ExpenseInterest (Income) ExpenseOther (Income) Expense
The effects of fair value, net investment and cash flow hedging:
Gain (Loss) on fair value hedging relationship:
Interest rate swaps contracts:
 Hedged items$———240————(45)—
 Derivatives designated as hedging instruments———(240)————45—
Gain (Loss) on net investment hedging relationship:
Cross currency interest rate swaps contracts:
   Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing———98————67—
   Amount of gain or (loss) recognized in AOCI———98————67—
Gain (Loss) on cash flow hedging relationship:
Forward foreign exchange contracts:
   Amount of gain or (loss) reclassified from AOCI into income 1(122)(15)—(3)—25912—1
   Amount of gain or (loss) recognized in AOCI 14571(108)—(40)(1)4733—5
Cross currency interest rate swaps contracts:
   Amount of gain or (loss) reclassified from AOCI into income———158————91—
   Amount of gain or (loss) recognized in AOCI$———673————(243)—
The following table is the effect of net investment hedges for the fiscal second quarters ended in 2025 and 2024:
Gain/(Loss)
Recognized In
Accumulated OCI
Location of Gain or (Loss)
Reclassified from Accumulated OCI Into Income		Gain/(Loss) Reclassified From
Accumulated OCI
Into Income
(Dollars in Millions)June 29, 2025June 30, 2024June 29, 2025June 30, 2024
Debt$(803)46Interest (income) expense——
Cross Currency interest rate swaps$(700)92Interest (income) expense——

The following table is the effect of net investment hedges for the fiscal six months ended in 2025 and 2024

Gain/(Loss)
Recognized In
Accumulated OCI		Location of Gain or (Loss)
Reclassified from Accumulated
OCI Into Income		Gain/(Loss) Reclassified From
Accumulated OCI
Into Income
(Dollars in Millions)June 29, 2025June 30, 2024June 29, 2025June 30, 2024
Debt$(1,119)130Interest (income) expense——
Cross Currency interest rate swaps$140820Interest (income) expense——
Schedule of Derivative Financial Instruments and Classification on Consolidated Balance Sheet
As of June 29, 2025, and December 29, 2024, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges:
Line item in the Consolidated Balance Sheet in which the hedged item is includedCarrying Amount of the Hedged Liability
Cumulative Amount of Fair Value
Hedging Gain/ (Loss) Included in the
Carrying Amount of the Hedged Liability
(Dollars in Millions)June 29, 2025December 29, 2024June 29, 2025December 29, 2024
Long-term Debt$8,2097,935(820)(1,132)
Schedule of Effect of Derivatives not Designated as Hedging Instruments
The following table is the effect of derivatives not designated as hedging instruments for the fiscal second quarters ended and fiscal six months ended 2025 and 2024:
Gain/(Loss)
Recognized In
Income on Derivative		Gain/(Loss)
Recognized In
Income on Derivative
(Dollars in Millions)Location of
Gain /(Loss)
Recognized in
Income on Derivative		Fiscal Second Quarter EndedFiscal Six Months Ended
Derivatives Not Designated as Hedging InstrumentsJune 29, 2025June 30, 2024June 29, 2025June 30, 2024
Foreign Exchange ContractsOther (income) expense$(19)204345
Summary of Activity Related to Equity Investments
The following table is a summary of the activity related to equity investments:
December 29, 2024June 29, 2025
(Dollars in Millions)Carrying Value
Changes in Fair Value Reflected in Net Income (1)
(Sales)/ Purchases/Other (2)
Carrying ValueNon Current Other Assets
Equity Investments with readily determinable value$451(57)59453453
Equity Investments without readily determinable value$773(26)76823823
(1)Recorded in Other (income)/expense, net
(2)Other includes impact of currency
Financial Assets and Liabilities at Fair Value
The Company’s significant financial assets and liabilities measured at fair value as of June 29, 2025 and December 29, 2024 were as follows:
 June 29, 2025December 29, 2024
(Dollars in Millions)Level 1Level 2Level 3Total
Total(1)
Derivatives designated as hedging instruments:     
Assets:     
Forward foreign exchange contracts $—1,006—1,006660
Interest rate contracts(2)
—431—4311,484
Total —1,437—1,4372,144
Liabilities:     
Forward foreign exchange contracts —774—774794
Interest rate contracts(2)
—6,234—6,2343,753
Total —7,008—7,0084,547
Derivatives not designated as hedging instruments:     
Assets:     
Forward foreign exchange contracts —57—5750
Liabilities:     
Forward foreign exchange contracts —72—7217
Other Investments:
Equity investments(3)
453——453451
Debt securities(4)
—2,094—2,0947,216
Other Liabilities:
Contingent consideration(5)
$——1,1571,1571,217
Gross to Net Derivative ReconciliationJune 29, 2025December 29, 2024
(Dollars in Millions)
Total Gross Assets$1,4942,194
Credit Support Agreement (CSA)(1,471)(2,172)
Total Net Asset2322
Total Gross Liabilities7,0804,564
Credit Support Agreement (CSA)(6,666)(4,412)
Total Net Liabilities$414152
Summarized information about changes in liabilities for contingent consideration for the fiscal second quarters ended June 29, 2025 and June 30, 2024 is as follows:
June 29, 2025June 30, 2024
(Dollars in Millions)
Beginning Balance$1,2171,092
Changes in estimated fair value(6)
(60)44
Additions—112
Payments——
Ending Balance$1,1571,248
(1)2024 assets and liabilities are all classified as Level 2 with the exception of equity investments of $451 million, which are classified as Level 1 and contingent consideration of $1,217 million, classified as Level 3.
(2)Includes cross currency interest rate swaps and interest rate swaps.
(3)Classified as non-current other assets.
(4)Classified within cash equivalents and current marketable securities.
(5)Includes $1,107 million and $1,217 million classified as non-current other liabilities as of June 29, 2025 and December 29, 2024, respectively. Includes $50 million classified as current liabilities as of June 29, 2025.
(6)Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense.
Marketable Securities
The Company's cash, cash equivalents and current marketable securities as of June 29, 2025 comprised:
(Dollars in Millions)
Carrying
Amount
Unrealized Gain
Estimated
Fair Value
Cash & Cash
Equivalents
Current
Marketable
Securities
Cash$3,246—3,2463,246—
U.S. reverse repurchase agreements8,040—8,0408,040—
Money market funds4,637—4,6374,637—
Time deposits(1)
863—863863—
   Subtotal 16,786—16,78616,786—
U.S. Gov’t securities1,673—1,6731,65914
Other sovereign securities193—1939499
Corporate debt securities228—22838190
   Subtotal available for sale debt(2)
$2,094—2,0941,791303
Total cash, cash equivalents and current marketable securities$18,880—18,88018,577303
(1)Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings.
(2)Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
Schedule of Available for Sale Securities Maturities
The contractual maturities of the available for sale securities as of June 29, 2025 are as follows:
(Dollars in Millions)Cost BasisFair Value
Due within one year$2,0752,075
Due after one year through five years1919
Due after five years through ten years——
Total debt securities$2,0942,094
Financial Liabilities not Measured at Fair Value
Financial instruments not measured at fair value
The following financial liabilities are held at carrying amount on the consolidated balance sheet as of June 29, 2025:
(Dollars in Millions)
Carrying
Amount
Estimated
Fair Value
Financial Liabilities  
Current Debt$11,52611,495
Non-Current Debt  
2.95% Notes due 2027
950984
0.95% Notes due 2027
1,4781,410
4.50% Notes due 2027(1)
749757
2.90% Notes due 2028
1,4981,460
1.150% Notes due 2028 (750MM Euro 1.1704)
881843
4.55% Notes due 2028(1)
748762
4.80% Notes due 2029
1,1461,181
6.95% Notes due 2029
299334
2.70% Notes due 2029 (600MM Euro 1.1704)(1)
706708
1.30% Notes due 2030
1,6761,521
4.70% Notes due 2030(1)
9951,022
4.90% Notes due 2031
1,1461,189
3.20% Notes due 2032 (700MM Euro 1.1704)
821834
4.85% Notes due 2032(1)
1,2421,281
4.95% Notes due 2033
499517
4.375% Notes due 2033
853847
3.050% Notes due 2033 ( 700MM Euro 1.1704)(1)
822822
4.95% Notes due 2034

847880
1.650% Notes due 2035 (1.5B Euro 1.1704)
1,7561,528
5.00% Notes due 2035(1)
1,2441,282
3.35% Notes due 2036 (800MM Euro 1.1704)

937939
3.587% Notes due 2036
905902
5.95% Notes due 2037
9941,103
3.625% Notes due 2037
1,3961,334
3.350% Notes due 2037 (1.0B Euro 1.1704)(1)
1,1751,160
3.40% Notes due 2038
993857
5.85% Notes due 2038
697761
4.50% Notes due 2040
542523
2.10% Notes due 2040
885684
4.85% Notes due 2041
298291
4.50% Notes due 2043
496459
3.55% Notes due 2044 (1.0B Euro 1.1704)
1,1031,135
3.60% Notes due 2045 (700MM Euro 1.1704)(1)
819792
3.73% Notes due 2046
1,9791,592
3.75% Notes due 2047
863798
3.50% Notes due 2048
744567
2.25% Notes due 2050
851580
5.25% Notes due 2054

843837
3.70% Notes due 2055 (1.0B Euro 1.1704)(1)
1,1721,118
2.45% Notes due 2060
1,102694
Other8588
Total Non-Current Debt$39,23537,376
(1) In the fiscal first quarter of 2025, the Company issued senior unsecured notes for approximately $9.2 billion. The net proceeds from this offering were used to fund the Intra-Cellular Therapies, Inc. acquisition which closed on April 2, 2025, and for general corporate purposes.
v3.25.2
Pensions and Other Benefit Plans (Tables)
 6 Months Ended
Jun. 29, 2025
Retirement Benefits [Abstract]  
Components of Net Periodic Benefit Cost
Components of net periodic benefit cost
Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans include the following components:
Fiscal Second Quarter EndedFiscal Six Months Ended
 Retirement PlansOther Benefit PlansRetirement PlansOther Benefit Plans
(Dollars in Millions)June 29, 2025June 30, 2024June 29, 2025June 30, 2024June 29, 2025June 30, 2024June 29, 2025June 30, 2024
Service cost$2192227269433446144138
Interest cost3563515352707703107104
Expected return on plan assets(599)(639)(1)(1)(1,186)(1,281)(3)(3)
Amortization of prior service cost/(credit)
(46)(46)(1)(1)(92)(92)(1)(1)
Recognized actuarial (gains)/losses85441513168873126
Curtailments and settlements—(8)———(8)——
Special termination benefits1———1———
Net periodic benefit cost/(credit)$16(76)13813231(145)278264
v3.25.2
Accumulated Other Comprehensive Income (Tables)
 6 Months Ended
Jun. 29, 2025
Equity [Abstract]  
Components of Accumulated Other Comprehensive Income
Components of other comprehensive income/(loss) consist of the following:
(Dollars in Millions)
Foreign
Currency
Translation
Gain/
(Loss) On
Securities
Employee
Benefit
Plans
Gain/
(Loss) On
Derivatives
& Hedges
Total
Accumulated
Other
Comprehensive
Income/(Loss)
December 29, 2024$(8,441)1(1,551)(1,750)(11,741)
Net change(3,739)(1)851,091(2,564)
June 29, 2025(12,180)0(1,466)(659)(14,305)
v3.25.2
Earnings Per Share (Tables)
 6 Months Ended
Jun. 29, 2025
Earnings Per Share [Abstract]  
Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share
The following is a reconciliation of basic net earnings per share to diluted net earnings per share:
 Fiscal Second Quarter EndedFiscal Six Months Ended
(Shares in Millions)June 29, 2025June 30, 2024June 29, 2025June 30, 2024
Basic net earnings per share$2.301.956.873.30
Average shares outstanding — basic2,406.32,406.82,406.72,407.5
Potential shares exercisable under stock option plans64.662.667.079.3
Less: shares which could be repurchased under treasury stock method(51.8)(47.4)(50.4)(58.3)
Average shares outstanding — diluted2,419.12,422.02,423.32,428.5
Diluted net earnings per share$2.291.936.823.27
(Shares in Millions)
The diluted net earnings per share calculation excluded the following number of shares related to stock options, as the exercise price of these options was greater than the average market value of the Company’s stock. 66.372.263.353.8
v3.25.2
Segments of Business and Geographic Areas (Tables)
 6 Months Ended
Jun. 29, 2025
Segment Reporting [Abstract]  
Sales By Segment Of Business
 Fiscal Second Quarter EndedFiscal Six Months Ended
(Dollars in Millions)June 29,
2025		June 30,
2024		Percent
Change		June 29,
2025		June 30,
2024
Percent
Change
INNOVATIVE MEDICINE
Oncology
U.S.
$3,3852,63628.4 %$6,3985,01927.5 %
International
2,9282,45519.3 5,5924,88514.5 
Worldwide
6,3125,09024.0 11,9909,90421.1 
CARVYKTI
U.S.
358167*676307*
International
8120*13236*
Worldwide
439186*808343*
DARZALEX
U.S.
2,0171,64123.0 3,8463,10523.9 
International
1,5211,23723.0 2,9302,46518.9 
Worldwide
3,5392,87823.0 6,7765,57021.7 
ERLEADA
U.S.
37831818.6 67060311.0 
International
53041827.0 1,00982222.9 
Worldwide
90873623.4 1,6791,42517.8 
IMBRUVICA
U.S.
239246(2.7)474511(7.3)
International
496525(5.4)9701,043(6.9)
Worldwide
735770(4.5)1,4441,554(7.0)
RYBREVANT/ LAZCLUZE(1)
U.S.
13952*25288*
International
4117*6928*
Worldwide
17969*320116*
TALVEY
U.S.
825938.0 15010936.7 
International
249*4217*
Worldwide
1066955.0 19212752.0 
TECVAYLI
U.S.
1141048.2 2192056.6 
International
523074.8 986356.0 
Worldwide
16613523.1 31726818.2 
 Fiscal Second Quarter EndedFiscal Six Months Ended
(Dollars in Millions)June 29,
2025		June 30,
2024		Percent
Change		June 29,
2025		June 30,
2024
Percent
Change
ZYTIGA / abiraterone acetate
U.S.
611(38.9)1320(31.9)
International
139154(9.8)257326(21.1)
Worldwide
145165(11.6)270346(21.7)
OTHER ONCOLOGY
U.S.
503736.9 977039.8 
International
4245(8.7)8486(2.5)
Worldwide
938311.7 18215616.4 
Immunology
U.S.
2,5052,978(15.9)4,7015,431(13.4)
International
1,4891,744(14.6)2,9993,538(15.2)
Worldwide
3,9934,722(15.4)7,7008,969(14.1)
REMICADE
U.S.
28323122.5 59749720.1 
U.S. Exports
3435(2.6)4462(28.7)
International
1381278.6 2812684.8 
Worldwide
45539315.9 92282711.5 
SIMPONI / SIMPONI ARIA
U.S.
30526714.0 59752114.4 
International
38727043.1 75356932.2 
Worldwide
69053728.6 1,3491,09123.7 
STELARA
U.S.
1,0781,855(41.9)2,0593,251(36.7)
International
5751,030(44.2)1,2192,085(41.5)
Worldwide
1,6532,885(42.7)3,2785,336(38.6)
TREMFYA
U.S.
79658935.2 1,3951,09827.1 
International
39131723.2 74761621.2 
Worldwide
1,18690631.0 2,1421,71425.0 
OTHER IMMUNOLOGY
U.S.
82*92*
International
00—00—
Worldwide
82*92*
Neuroscience
U.S.
1,3771,10224.9 2,3452,1568.7 
International
674679(0.8)1,3531,428(5.2)
Worldwide
2,0511,78215.1 3,6983,5853.2 
CAPLYTA(2)
U.S.
211—*211—*
International
——— ——— 
Worldwide
211—*211—*
 Fiscal Second Quarter EndedFiscal Six Months Ended
(Dollars in Millions)June 29,
2025		June 30,
2024		Percent
Change		June 29,
2025		June 30,
2024
Percent
Change
CONCERTA / methylphenidate
U.S.
2434(27.7)6275(16.6)
International
1391297.5 249265(6.0)
Worldwide
1641630.2 312340(8.3)
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
U.S.
732784(6.7)1,3571,549(12.4)
International
260269(3.5)537561(4.2)
Worldwide
9921,054(5.9)1,8952,110(10.2)
SPRAVATO
U.S.
36622661.1 64241753.7 
International
504412.8 937818.1 
Worldwide
41427153.3 73449648.1 
OTHER NEUROSCIENCE
U.S.
4557(23.5)73115(37.0)
International
226237(4.7)474524(9.5)
Worldwide
270294(8.4)547639(14.4)
Pulmonary Hypertension
U.S.
7997437.6 1,5431,5092.3 
International
3142965.8 5955792.6 
Worldwide
1,1131,0397.1 2,1382,0882.4 
OPSUMIT/OPSYNVI
U.S.4033766.9 7667324.6 
International1801715.4 339340(0.3)
Worldwide5825486.4 1,1041,0723.0 
UPTRAVI
U.S.3823499.4 7477410.8 
International947622.4 18015217.9 
Worldwide 47642611.7 9278943.7 
OTHER PULMONARY HYPERTENSION
U.S.
1617(12.4)3135(12.6)
International4049(18.5)7788(12.4)
Worldwide 5567(16.9)107123(12.5)
Infectious Diseases
U.S.
320334(4.3)635658(3.6)
International
484631(23.4)9711,128(13.9)
Worldwide
803965(16.8)1,6051,786(10.1)
EDURANT / rilpivirine
U.S.
68(25.4)1416(13.6)
International
35428823.0 70460316.7 
Worldwide
36029721.6 71862015.9 
 Fiscal Second Quarter EndedFiscal Six Months Ended
(Dollars in Millions)June 29,
2025		June 30,
2024		Percent
Change		June 29,
2025		June 30,
2024
Percent
Change
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
U.S.
312321(3.0)617635(2.9)
International
85117(27.0)183221(17.2)
Worldwide
396438(9.4)799856(6.6)
OTHER INFECTIOUS DISEASES
U.S.
25(51.8)47(37.4)
International
45227(80.5)84304(72.5)
Worldwide
47233(79.8)88311(71.7)
Cardiovascular / Metabolism / Other
U.S.7767178.2 1,6311,34821.0 
International154176(12.3)312373(16.2)
Worldwide9308924.2 1,9431,72112.9 
XARELTO
U.S.6215875.6 1,3111,10518.6 
International——— ——— 
Worldwide6215875.6 1,3111,10518.6 
OTHER
U.S.15512920.0 32024331.6 
International154176(12.3)312373(16.2)
Worldwide3093051.4 6326162.7 
TOTAL INNOVATIVE MEDICINE  
U.S.9,1618,5107.6 17,25316,1227.0 
International6,0415,9801.0 11,82211,930(0.9)
Worldwide15,20214,4904.9 29,07528,0523.6 
MEDTECH
Cardiovascular
U.S.1,3641,11921.9 2,6252,14422.4 
International94875325.9 1,7901,53416.7 
Worldwide2,3131,87323.5 4,4163,67920.0 
ELECTROPHYSIOLOGY
U.S.7417055.1 1,4251,3972.0 
International72861817.8 1,3661,2707.6 
Worldwide1,4681,32311.0 2,7912,6674.7 
ABIOMED
U.S.36030916.6 69961214.2 
International897225.0 17013922.4 
Worldwide44837918.2 86875015.7 
SHOCKWAVE(3)
U.S.23377*43977*
International580*1100*
Worldwide29277*55077*
 Fiscal Second Quarter EndedFiscal Six Months Ended
(Dollars in Millions)June 29,
2025		June 30,
2024		Percent
Change		June 29,
2025		June 30,
2024
Percent
Change
OTHER CARDIOVASCULAR
U.S.31295.4 63596.3 
International726413.4 14412614.2 
Worldwide1049310.8 20718511.7 
Orthopaedics
U.S.1,4201,422(0.2)2,8042,870(2.3)
International885890(0.5)1,7421,782(2.2)
Worldwide2,3052,312(0.3)4,5464,652(2.3)
HIPS
U.S.2712652.1 534535(0.2)
International150152(1.0)296304(2.5)
Worldwide4214171.0 830839(1.1)
KNEES
U.S.226230(1.9)457472(3.1)
International1641630.0 322323(0.5)
Worldwide389394(1.1)778795(2.0)
TRAUMA
U.S.5014980.7 1,0031,0020.1 
International2672602.2 5375212.9 
Worldwide7687591.2 1,5401,5241.1 
SPINE, SPORTS & OTHER
U.S.422430(1.7)810862(6.0)
International305314(2.7)588634(7.2)
Worldwide727743(2.1)1,3981,495(6.5)
Surgery
U.S.1,0439954.8 2,0451,9823.2 
International1,5121,4931.3 2,9062,922(0.5)
Worldwide2,5552,4882.7 4,9514,9041.0 
ADVANCED
U.S.4774662.2 9349122.4 
International6876751.9 1,3031,316(1.0)
Worldwide1,1641,1412.0 2,2372,2280.4 
GENERAL
U.S.5675287.2 1,1111,0703.8 
International8258180.9 1,6031,606(0.1)
Worldwide1,3911,3463.3 2,7142,6761.4
Vision
U.S.5575236.5 1,1231,0704.9 
International8137636.5 1,5261,4733.6 
Worldwide1,3691,2856.5 2,6482,5434.1 
 Fiscal Second Quarter EndedFiscal Six Months Ended
(Dollars in Millions)June 29,
2025		June 30,
2024		Percent
Change		June 29,
2025		June 30,
2024
Percent
Change
CONTACT LENSES / OTHER
U.S.4294094.8 8818473.9 
International5365095.4 1,0039812.3 
Worldwide9659185.1 1,8841,8283.1 
SURGICAL
U.S.12811312.6 2422238.5 
International2772548.8 5234926.2 
Worldwide4033679.9 7647156.9 
TOTAL MEDTECH    
U.S.4,3834,0598.0 8,5968,0676.6 
International4,1583,8986.7 7,9657,7113.3 
Worldwide8,5417,9577.3 16,56115,7785.0 
WORLDWIDE      
U.S.13,54412,5697.8 25,84924,1896.9 
International10,1999,8783.2 19,78719,6410.7 
Worldwide$23,74322,4475.8 %$45,63643,8304.1 %
*    Percentage greater than 100% or not meaningful
(1) Includes the sales of RYBREVANT and RYBREVANT + LAZCLUZE
(2) Acquired with the Intra-Cellular Therapies acquisition on April 2, 2025
(3) Acquired on May 31, 2024
Operating Profit by Segment of Business
 Fiscal Second Quarter Ended
(Dollars in Millions)June 29,
2025		June 30,
2024
Innovative Medicine(1)
MedTech(2)
Total
Innovative Medicine(1)
MedTech(2)
Total
Sales to customers$15,2028,54114,4907,957
Cost of products sold3,9783,6383,6033,248
Selling, marketing and administrative2,7892,8622,6652,671
Research and development expense2,8696472,722718
Other segment items (3)
1419041231
Segment income before tax$5,5521,2046,7565,4591,0896,548
(Income)/Expense not allocated to segments (4)
265800
Earnings before provision for taxes on income$6,491$5,748
Fiscal Six Months Ended
Sales to customers$29,07516,56128,05215,778
Cost of products sold7,9986,9646,9736,368
Selling, marketing and administrative5,0505,5185,1035,253
Research and development expense5,4171,3245,6181,364
Other segment items (3)
(152)130(70)184
Segment income before tax$10,7622,62513,38710,4282,60913,037
(Income)/Expense not allocated to segments (4)
(6,735)3,575
Earnings before provision for taxes on income$20,122$9,462
(1) Innovative Medicine includes:
•Intangible amortization expense of $0.8 billion and $0.7 billion in the fiscal second quarter of 2025 and 2024, respectively.
Intangible amortization expense of $1.4 billion in both the fiscal six months of 2025 and 2024.
•Acquisition and integration related expense of $0.2 billion in both the fiscal second quarter of 2025 and fiscal six months of 2025, primarily related to the Intra-Cellular acquisition.
•An In-process research and development impairment of $0.2 billion in the fiscal second quarter and fiscal six months of 2024 associated with the M710 (biosimilar) asset acquired from Momenta in 2020.
•Restructuring income of $0.1 billion in the fiscal second quarter of 2024 and a restructuring related charge of $0.1 billion in the fiscal six months of 2024.
(2)    MedTech includes:
•Intangible amortization expense of $0.5 billion and $0.4 billion in the fiscal second quarter of 2025 and 2024, respectively.
Intangible amortization expense of $1.0 billion and $0.8 billion in the fiscal six months of 2025 and 2024, respectively.
•Acquisition, integration and divestiture related net expense of $0.1 billion in the fiscal six months of 2025. Acquisition and integration related expense of $0.4 billion and $0.5 billion, in the fiscal second quarter and fiscal six months of 2024, respectively, primarily driven by the Abiomed and Shockwave acquisitions.
•A restructuring related charge of $0.1 billion in both the fiscal second quarter and fiscal six months of 2025 and 2024. Refer to Note 12 for additional details.
(3)    Other segment expenses for each reportable segment include charges related to other income and expense, restructuring activities and impairment charges related to in-process research and development.
(4) Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal six months of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal second quarter and fiscal six months of 2024 includes charges for talc matters of $0.3 billion and $3.0 billion, respectively. For additional details related to talc refer to Note 11 to the Consolidated Financial Statements. The fiscal second quarter and six months of 2024 includes a loss of approximately $0.4 billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock.
Identifiable Assets
(Dollars in Millions)June 29, 2025December 29, 2024
Innovative Medicine$75,48757,070
MedTech86,74584,322
Total162,232141,392
General corporate (1)
31,15738,712
Worldwide total$193,389180,104
(1)General corporate includes cash, cash equivalents, marketable securities and other corporate assets.
Additions to Property,
Plant & Equipment		Depreciation and
Amortization
(Dollars in Millions)June 29, 2025June 30, 2024June 29, 2025June 30, 2024
Innovative Medicine$687553$1,9251,861
MedTech1,0711,0741,6781,552
Segments total1,7581,6273,6033,413
General corporate80156112184
Worldwide total$1,8381,783$3,7153,597
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas
Sales by geographic area
 Fiscal Second Quarter EndedFiscal Six Months Ended
(Dollars in Millions)June 29, 2025June 30, 2024Percent
Change		June 29, 2025June 30, 2024Percent Change
United States$13,54412,5697.8 %$25,84924,1896.9 %
Europe5,3875,2143.3 10,49710,3771.1 
Western Hemisphere, excluding U.S.1,2061,212(0.5)2,3732,406(1.3)
Asia-Pacific, Africa3,6063,4524.4 6,9176,8580.9 
Total$23,74322,4475.8 %$45,63643,8304.1 %
v3.25.2
Acquisitions and Divestitures (Tables)
 6 Months Ended
Jun. 29, 2025
Business Combination [Abstract]  
Schedule of Preliminary Amounts Recognized for Assets Acquired and Liabilities Assumed
The following table summarizes the preliminary fair value of assets acquired and liabilities assumed as of the acquisition date and is based on the best estimate of management, which is subject to change within the measurement period.

(Dollars in Billions)April 2, 2025
Assets acquired:
Cash and cash equivalents $0.2
Marketable securities0.6
Other current & non-current assets0.3
Amortizable intangible asset (1)
5.2
Acquired in-process research and development (1)
8.3
Goodwill (2)
2.9
Total assets acquired$17.5
Liabilities assumed:
Deferred taxes$2.8
Other current & non-current liabilities0.2
Total liabilities assumed$3.0
Total assets acquired and liabilities assumed$14.5
(1) The estimated fair values of the intangible assets acquired were determined using the multi-period excess earnings method. The amortizable intangible asset relates to the currently marketed product, Caplyta, which has an estimated useful life of 8 years. The acquired in-process research and development includes two assets, one related to certain unapproved indications of lumateperone and another related to a compound being studied to treat psychosis and agitation in patients with Alzheimer’s disease and generalized anxiety disorder. The fair value of the in-process research and development assets were calculated assuming a discount rate of 11.5% and 12.5%, respectively. Additionally, the cash flow projections assumed a probability of success factor of 95% and approximately 34-50% (depending on indication being studied), respectively.

(2) Goodwill is primarily attributable to intangible assets that did not qualify for separate recognition and future projects or products currently unidentified. Goodwill is not expected to be deductible for tax purposes.
v3.25.2
Legal Proceedings (Tables)
 6 Months Ended
Jun. 29, 2025
Commitments and Contingencies Disclosure [Abstract]  
Summary Of Claims In Pending Lawsuits
Product or product category
Number of plaintiffs
Body powders containing talc, primarily JOHNSON’S Baby Powder70,030
DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System40
PINNACLE Acetabular Cup System860
Pelvic meshes5,350
ETHICON PHYSIOMESH Flexible Composite Mesh120
ELMIRON920
v3.25.2
Restructuring (Tables)
 6 Months Ended
Jun. 29, 2025
Restructuring and Related Activities [Abstract]  
Schedule of Restructuring Reserve
The following table summarizes the restructuring expenses for 2025 and 2024:
(Pre-tax Dollars in Millions)Q2 2025Q2 2024Q2 YTD 2025Q2 YTD 2024
MedTech Segment Surgery franchise(1)
$29—29—
MedTech Segment Orthopaedics franchise(2)
505210579
Innovative Medicine Segment(3)
—(63)—81
Total Programs$79(11)134160
(1)Included in Restructuring on the Consolidated Statement of Earnings in the fiscal second quarter and fiscal six months of 2025.
(2)Included $35 million in Restructuring and $15 million in Cost of products sold on the Consolidated Statement of Earnings in the fiscal second quarter of 2025. Included $52 million in Restructuring, $23 million in Cost of products sold and $30 million in Other (Income)/Expense on the Consolidated Statement of Earnings in the fiscal six months of 2025. Included $50 million in Restructuring and $2 million in Cost of products sold on the Consolidated Statement of Earnings in the fiscal second quarter of 2024. Included $70 million in Restructuring and $9 million in Cost of products sold on the Consolidated Statement of Earnings in the fiscal six months of 2024.
(3)Included in Restructuring on the Consolidated Statement of Earnings. This program was completed in the fiscal fourth quarter of 2024.
v3.25.2
Summary of Significant Accounting Policies - Narrative (Details) - USD ($)
$ in Millions
Jun. 29, 2025
Dec. 29, 2024
Accounting Policies [Abstract]    
Supplier finance program, payment timing, period 90 days  
Supplier finance program, obligation $ 700 $ 800
v3.25.2
Inventories (Details) - USD ($)
$ in Millions
Jun. 29, 2025
Dec. 29, 2024
Inventory Disclosure [Abstract]    
Raw materials and supplies $ 2,389 $ 2,337
Goods in process 3,971 2,815
Finished goods 7,052 7,292
Total inventories $ 13,412 $ 12,444
v3.25.2
Intangible Assets and Goodwill (Details) - USD ($)
$ in Millions
Jun. 29, 2025
Dec. 29, 2024
Intangible assets with indefinite lives:    
Total intangible assets — net $ 49,835 $ 37,618
Purchased In-Process Research And Development    
Intangible assets with indefinite lives:    
Total intangible assets with indefinite lives 19,896 12,281
Patents And Trademarks    
Intangible assets with definite lives:    
Finite-lived intangible assets, gross 53,272 44,695
Less accumulated amortization (30,756) (26,124)
Finite-lived intangible assets, net 22,516 18,571
Customer relationships and other intangible assets    
Intangible assets with definite lives:    
Finite-lived intangible assets, gross 21,910 20,310
Less accumulated amortization (14,487) (13,544)
Finite-lived intangible assets, net $ 7,423 $ 6,766
v3.25.2
Intangible Assets and Goodwill - Goodwill By Segment (Details)
$ in Millions
 6 Months Ended
Jun. 29, 2025
USD ($)
Goodwill [Roll Forward]  
Goodwill Beginning of Period $ 44,200
Goodwill, related to acquisitions 2,876
Goodwill, related to divestitures (29)
Currency translation/Other 1,070
Goodwill End of Period 48,117
Innovative Medicine  
Goodwill [Roll Forward]  
Goodwill Beginning of Period 10,692
Goodwill, related to acquisitions 2,876
Goodwill, related to divestitures 0
Currency translation/Other 758
Goodwill End of Period 14,326
MedTech  
Goodwill [Roll Forward]  
Goodwill Beginning of Period 33,508
Goodwill, related to acquisitions 0
Goodwill, related to divestitures (29)
Currency translation/Other 312
Goodwill End of Period $ 33,791
v3.25.2
Intangible Assets and Goodwill - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 29, 2025
Jun. 30, 2024
Jun. 29, 2025
Jun. 30, 2024
Finite-Lived Intangible Assets [Line Items]        
Amortization expense of amortizable intangible assets $ 1,300 $ 1,100 $ 2,400 $ 2,200
Patents And Trademarks        
Finite-Lived Intangible Assets [Line Items]        
Useful life (in years) 13 years   13 years  
Customer relationships and other intangible assets        
Finite-Lived Intangible Assets [Line Items]        
Useful life (in years) 19 years   19 years  
v3.25.2
Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)
$ in Millions
Jun. 29, 2025
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
2025 $ 4,500
2026 4,000
2027 3,400
2028 2,700
2029 $ 2,600
v3.25.2
Fair Value Measurements - Narrative (Details) - USD ($)
$ in Millions
 6 Months Ended
Jun. 29, 2025
Dec. 29, 2024
Derivative [Line Items]    
Accumulated other comprehensive loss on derivatives, after tax $ (700)  
Hedging exposure 18 months  
Weighted average interest rate on non-current debt 3.57%  
Excess of carrying value over fair value of debt $ 2,000  
Current Debt 11,526 $ 5,983
Commercial Paper    
Derivative [Line Items]    
Current Debt $ 8,500  
Weighted average interest rate 4.28%  
Term 2 months  
Forward foreign exchange contracts    
Derivative [Line Items]    
Collateral already posted, aggregate fair value $ 5,200  
Derivative, notional amount 47,700 45,100
Cross currency interest rate swaps    
Derivative [Line Items]    
Derivative, notional amount 40,900 40,500
Interest Rate Swap    
Derivative [Line Items]    
Derivative, notional amount $ 9,000 $ 9,000
v3.25.2
Fair Value Measurements - Summary of Derivative Activity (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 29, 2025
Jun. 30, 2024
Jun. 29, 2025
Jun. 30, 2024
Other (income) expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) reclassified from AOCI into income $ 0 $ 0 $ 0 $ 0
Cross currency interest rate swaps | Other (income) expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) reclassified from AOCI into income 0 0 0 0
Fair Value Hedging | Interest Rate Swap | Sales to customers        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 0 0 0 0
Amount of gain or (loss) recognized in AOCI 0 0 0 0
Fair Value Hedging | Interest Rate Swap | Cost of products sold        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 0 0 0 0
Amount of gain or (loss) recognized in AOCI 0 0 0 0
Fair Value Hedging | Interest Rate Swap | Research and Development Expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 0 0 0 0
Amount of gain or (loss) recognized in AOCI 0 0 0 0
Fair Value Hedging | Interest Rate Swap | Interest (income)/Interest expense, net        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 52 (53) 240 (45)
Amount of gain or (loss) recognized in AOCI (52) 53 (240) 45
Fair Value Hedging | Interest Rate Swap | Other (income) expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 0 0 0 0
Amount of gain or (loss) recognized in AOCI 0 0 0 0
Fair Value Hedging | Cross currency interest rate swaps | Sales to customers        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing     0 0
Amount of gain or (loss) recognized in AOCI     0 0
Fair Value Hedging | Cross currency interest rate swaps | Cost of products sold        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing     0 0
Amount of gain or (loss) recognized in AOCI     0 0
Fair Value Hedging | Cross currency interest rate swaps | Research and Development Expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing     0 0
Amount of gain or (loss) recognized in AOCI     0 0
Fair Value Hedging | Cross currency interest rate swaps | Interest (income)/Interest expense, net        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing     98 67
Amount of gain or (loss) recognized in AOCI     98 67
Fair Value Hedging | Cross currency interest rate swaps | Other (income) expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing     0 0
Amount of gain or (loss) recognized in AOCI     0 0
Net Investment Hedging | Net Investment Hedging | Sales to customers        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 0 0    
Amount of gain or (loss) recognized in AOCI 0 0    
Net Investment Hedging | Net Investment Hedging | Cost of products sold        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 0 0    
Amount of gain or (loss) recognized in AOCI 0 0    
Net Investment Hedging | Net Investment Hedging | Research and Development Expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 0 0    
Amount of gain or (loss) recognized in AOCI 0 0    
Net Investment Hedging | Net Investment Hedging | Interest (income)/Interest expense, net        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 48 33    
Amount of gain or (loss) recognized in AOCI 48 33    
Net Investment Hedging | Net Investment Hedging | Other (income) expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing 0 0    
Amount of gain or (loss) recognized in AOCI 0 0    
Cash Flow Hedging | Forward foreign exchange contracts | Sales to customers        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) recognized in AOCI 11 2 14 (1)
Amount of gain or (loss) reclassified from AOCI into income 2 (1) 1 0
Cash Flow Hedging | Forward foreign exchange contracts | Cost of products sold        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) recognized in AOCI 466 66 571 47
Amount of gain or (loss) reclassified from AOCI into income (132) 94 (122) 259
Cash Flow Hedging | Forward foreign exchange contracts | Research and Development Expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) recognized in AOCI (72) 11 (108) 33
Amount of gain or (loss) reclassified from AOCI into income (16) 8 (15) 12
Cash Flow Hedging | Forward foreign exchange contracts | Interest (income)/Interest expense, net        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) recognized in AOCI 0 0 0 0
Amount of gain or (loss) reclassified from AOCI into income 0 0 0 0
Cash Flow Hedging | Forward foreign exchange contracts | Other (income) expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) recognized in AOCI (29) 1 (40) 5
Amount of gain or (loss) reclassified from AOCI into income (3) 3 (3) 1
Cash Flow Hedging | Cross currency interest rate swaps | Sales to customers        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) recognized in AOCI 0 0 0 0
Amount of gain or (loss) reclassified from AOCI into income 0 0 0 0
Cash Flow Hedging | Cross currency interest rate swaps | Cost of products sold        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) recognized in AOCI 0 0 0 0
Amount of gain or (loss) reclassified from AOCI into income 0 0 0 0
Cash Flow Hedging | Cross currency interest rate swaps | Research and Development Expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) recognized in AOCI 0 0 0 0
Amount of gain or (loss) reclassified from AOCI into income 0 0 0 0
Cash Flow Hedging | Cross currency interest rate swaps | Interest (income)/Interest expense, net        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) recognized in AOCI 108 (38) 673 (243)
Amount of gain or (loss) reclassified from AOCI into income 76 42 158 91
Cash Flow Hedging | Cross currency interest rate swaps | Other (income) expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) recognized in AOCI 0 0 0 0
Amount of gain or (loss) reclassified from AOCI into income $ 0 $ 0 $ 0 $ 0
v3.25.2
Fair Value Measurements - Derivatives, Balance Sheet Location (Details) - USD ($)
$ in Millions
Jun. 29, 2025
Dec. 29, 2024
Derivative [Line Items]    
Carrying Amount of the Hedged Liability $ 7,080 $ 4,564
Designated as Hedging Instrument    
Derivative [Line Items]    
Carrying Amount of the Hedged Liability 8,209 7,935
Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability $ (820) $ (1,132)
v3.25.2
Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 29, 2025
Jun. 30, 2024
Jun. 29, 2025
Jun. 30, 2024
Not Designated as Hedging Instrument | Forward foreign exchange contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain/(Loss) Recognized In Income on Derivative $ (19) $ 20 $ 43 $ 45
v3.25.2
Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 29, 2025
Jun. 30, 2024
Jun. 29, 2025
Jun. 30, 2024
Derivative Instruments, Gain (Loss) [Line Items]        
Gain/(Loss) Recognized In Accumulated OCI $ (803) $ 46 $ (1,119) $ 130
Other Income Expense Net        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) reclassified from AOCI into income 0 0 0 0
Cross Currency Interest Rate Contract        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain/(Loss) Recognized In Accumulated OCI (700) 92 140 820
Cross Currency Interest Rate Contract | Other Income Expense Net        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain or (loss) reclassified from AOCI into income $ 0 $ 0 $ 0 $ 0
v3.25.2
Fair Value Measurements - Summary of Activity Related to Equity Investments (Details) - USD ($)
$ in Millions
 6 Months Ended
Jun. 29, 2025
Dec. 29, 2024
Equity Investment [Roll Forward]    
Non Current Other Assets $ 12,189 $ 11,414
Equity Securities | Equity Investments with readily determinable value    
Equity Investment [Roll Forward]    
Carrying value, beginning of period 451  
Equity, Fair Value Adjustment (57)  
Sales/ Purchases/Other 59  
Carrying value, end of period 453  
Non Current Other Assets 453  
Equity Securities | Equity Investments without readily determinable value    
Equity Investment [Roll Forward]    
Carrying value, beginning of period 773  
Equity, Fair Value Adjustment (26)  
Sales/ Purchases/Other 76  
Carrying value, end of period 823  
Non Current Other Assets $ 823  
v3.25.2
Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($)
$ in Millions
 6 Months Ended
Jun. 29, 2025
Jun. 30, 2024
Dec. 29, 2024
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets $ 1,437    
Derivatives designated as hedging instruments : Liabilities 7,008    
Available-for-sale Securities, Equity Securities 453   $ 451
Available-for-sale Securities 2,094   7,216
Contingent consideration 1,157   1,217
Total Gross Assets 1,494   2,194
Credit Support Agreement (CSA) (1,471)   (2,172)
Total Net Asset 23   22
Total Gross Liabilities 7,080   4,564
Credit Support Agreement (CSA) (6,666)   (4,412)
Total Net Liabilities 414   152
Beginning Balance 1,217 $ 1,092  
Changes in estimated fair value(6) (60) 44  
Additions 0 112  
Payments 0 0  
Ending Balance 1,157 $ 1,248  
Other Noncurrent Liabilities      
Financial assets and liabilities at fair value      
Contingent consideration 1,107   1,217
Other Current Liabilities      
Financial assets and liabilities at fair value      
Contingent consideration 50    
Quoted prices in active markets for identical assets and liabilities Level 1      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 0    
Derivatives designated as hedging instruments : Liabilities 0    
Available-for-sale Securities, Equity Securities 453   451
Available-for-sale Securities 0    
Contingent consideration 0    
Significant other observable inputs Level 2      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 1,437   2,144
Derivatives designated as hedging instruments : Liabilities 7,008   4,547
Available-for-sale Securities, Equity Securities 0    
Available-for-sale Securities 2,094    
Contingent consideration 0    
Significant unobservable inputs Level 3      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 0    
Derivatives designated as hedging instruments : Liabilities 0    
Available-for-sale Securities, Equity Securities 0    
Available-for-sale Securities 0    
Contingent consideration 1,157   1,217
Interest Rate Contract      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 431    
Derivatives designated as hedging instruments : Liabilities 6,234    
Interest Rate Contract | Quoted prices in active markets for identical assets and liabilities Level 1      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 0    
Derivatives designated as hedging instruments : Liabilities 0    
Interest Rate Contract | Significant other observable inputs Level 2      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 431   1,484
Derivatives designated as hedging instruments : Liabilities 6,234   3,753
Interest Rate Contract | Significant unobservable inputs Level 3      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 0    
Derivatives designated as hedging instruments : Liabilities 0    
Forward foreign exchange contracts      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 1,006    
Derivatives designated as hedging instruments : Liabilities 774    
Derivatives not designated as hedging instruments : Assets 57    
Derivatives not designated as hedging instruments : Liabilities 72    
Forward foreign exchange contracts | Quoted prices in active markets for identical assets and liabilities Level 1      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 0    
Derivatives designated as hedging instruments : Liabilities 0    
Derivatives not designated as hedging instruments : Assets 0    
Derivatives not designated as hedging instruments : Liabilities 0    
Forward foreign exchange contracts | Significant other observable inputs Level 2      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 1,006   660
Derivatives designated as hedging instruments : Liabilities 774   794
Derivatives not designated as hedging instruments : Assets 57   50
Derivatives not designated as hedging instruments : Liabilities 72   $ 17
Forward foreign exchange contracts | Significant unobservable inputs Level 3      
Financial assets and liabilities at fair value      
Derivatives designated as hedging instruments : Assets 0    
Derivatives designated as hedging instruments : Liabilities 0    
Derivatives not designated as hedging instruments : Assets 0    
Derivatives not designated as hedging instruments : Liabilities $ 0    
v3.25.2
Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details) - USD ($)
$ in Millions
 6 Months Ended
Jun. 29, 2025
Dec. 29, 2024
Debt Securities, Available-for-sale [Abstract]    
Available-for-sale Securities - Estimated Fair Value $ 2,094 $ 7,216
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents 18,577 24,105
Marketable securities 303 $ 417
Total cash, cash equivalents and current marketable securities, Carrying Amount 18,880  
Total cash, cash equivalents and current marketable securities, Unrealized Gain 0  
Total cash, cash equivalents and current marketable securities, Estimated Fair Value 18,880  
Excess of carrying value over fair value of debt 2,000  
Held-to-maturity Securities    
Debt Securities, Held-to-maturity [Abstract]    
Held-to-maturity Securities - Carrying Amount 16,786  
Held-to-maturity Securities, Unrecognized Gain 0  
Held-to-maturity Securities - Estimated Fair Value 16,786  
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents 16,786  
Marketable securities 0  
Held-to-maturity Securities | Cash    
Debt Securities, Held-to-maturity [Abstract]    
Held-to-maturity Securities - Carrying Amount 3,246  
Held-to-maturity Securities, Unrecognized Gain 0  
Held-to-maturity Securities - Estimated Fair Value 3,246  
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents 3,246  
Marketable securities 0  
Held-to-maturity Securities | U.S. reverse repurchase agreements    
Debt Securities, Held-to-maturity [Abstract]    
Held-to-maturity Securities - Carrying Amount 8,040  
Held-to-maturity Securities, Unrecognized Gain 0  
Held-to-maturity Securities - Estimated Fair Value 8,040  
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents 8,040  
Marketable securities 0  
Held-to-maturity Securities | Money market funds    
Debt Securities, Held-to-maturity [Abstract]    
Held-to-maturity Securities - Carrying Amount 4,637  
Held-to-maturity Securities, Unrecognized Gain 0  
Held-to-maturity Securities - Estimated Fair Value 4,637  
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents 4,637  
Marketable securities 0  
Held-to-maturity Securities | Time deposits(1)    
Debt Securities, Held-to-maturity [Abstract]    
Held-to-maturity Securities - Carrying Amount 863  
Held-to-maturity Securities, Unrecognized Gain 0  
Held-to-maturity Securities - Estimated Fair Value 863  
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents 863  
Marketable securities 0  
Available-for-sale Securities    
Debt Securities, Available-for-sale [Abstract]    
Available-for-sale Securities - Carrying Amount 2,094  
Available-for-sale Securities, Unrecognized Gain 0  
Available-for-sale Securities - Estimated Fair Value 2,094  
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents 1,791  
Marketable securities 303  
Available-for-sale Securities | U.S. Gov’t securities    
Debt Securities, Available-for-sale [Abstract]    
Available-for-sale Securities - Carrying Amount 1,673  
Available-for-sale Securities - Estimated Fair Value 1,673  
Available-for-sale Securities | Non-U.S. sovereign securities    
Debt Securities, Available-for-sale [Abstract]    
Available-for-sale Securities - Carrying Amount 193  
Available-for-sale Securities - Estimated Fair Value 193  
Available-for-sale Securities | Corporate debt securities(1)    
Debt Securities, Available-for-sale [Abstract]    
Available-for-sale Securities - Carrying Amount 228  
Available-for-sale Securities - Estimated Fair Value 228  
Available-for-sale Securities | Non-U.S. sovereign securities    
Debt Securities, Available-for-sale [Abstract]    
Available-for-sale Securities, Unrecognized Gain 0  
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents 94  
Marketable securities 99  
Available-for-sale Securities | Corporate debt securities(1)    
Debt Securities, Available-for-sale [Abstract]    
Available-for-sale Securities, Unrecognized Gain 0  
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents 38  
Marketable securities 190  
Available-for-sale Securities | U.S. Gov’t securities    
Debt Securities, Available-for-sale [Abstract]    
Available-for-sale Securities, Unrecognized Gain 0  
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]    
Cash and Cash Equivalents 1,659  
Marketable securities $ 14  
v3.25.2
Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)
$ in Millions
Jun. 29, 2025
USD ($)
Cost Basis  
Due within one year $ 2,075
Due after one year through five years 19
Due after five years through ten years 0
Total debt securities 2,094
Fair Value  
Due within one year 2,075
Due after one year through five years 19
Due after five years through ten years 0
Total debt securities $ 2,094
v3.25.2
Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)
$ in Millions
Jun. 29, 2025
USD ($)
Jun. 29, 2025
EUR (€)
Mar. 30, 2025
USD ($)
Dec. 29, 2024
USD ($)
Financial Liabilities        
Current Debt $ 11,526     $ 5,983
Non-Current Debt        
Non-Current Debt 39,235     $ 30,651
Unsecured Notes        
Non-Current Debt        
Debt instrument, face amount     $ 9,200  
Carrying Amount        
Financial Liabilities        
Current Debt 11,526      
Non-Current Debt        
Non-Current Debt 39,235      
Estimated Fair Value        
Financial Liabilities        
Current Debt 11,495      
Non-Current Debt        
Non-Current Debt $ 37,376      
2.95% Notes due 2027        
Non-Current Debt        
Stated interest rate (as a percent) 2.95% 2.95%    
2.95% Notes due 2027 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 950      
2.95% Notes due 2027 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 984      
0.95% Notes due 2027        
Non-Current Debt        
Stated interest rate (as a percent) 0.95% 0.95%    
0.95% Notes due 2027 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 1,478      
0.95% Notes due 2027 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 1,410      
4.50% Notes due 2027        
Non-Current Debt        
Stated interest rate (as a percent) 4.50% 4.50%    
4.50% Notes due 2027 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 749      
4.50% Notes due 2027 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 757      
2.90% Notes due 2028        
Non-Current Debt        
Stated interest rate (as a percent) 2.90% 2.90%    
2.90% Notes due 2028 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 1,498      
2.90% Notes due 2028 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 1,460      
1.150% Notes due 2028 (750MM Euro 1.1704)        
Non-Current Debt        
Stated interest rate (as a percent) 1.15% 1.15%    
Debt instrument, face amount | €   € 750,000,000    
Foreign exchange rate 1.1704 1.1704    
1.150% Notes due 2028 (750MM Euro 1.1704) | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 881      
1.150% Notes due 2028 (750MM Euro 1.1704) | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 843      
4.55% Notes Due 2029        
Non-Current Debt        
Stated interest rate (as a percent) 4.55% 4.55%    
4.55% Notes Due 2029 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 748      
4.55% Notes Due 2029 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 762      
4.80% Notes due 2029        
Non-Current Debt        
Stated interest rate (as a percent) 4.80% 4.80%    
4.80% Notes due 2029 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 1,146      
4.80% Notes due 2029 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 1,181      
6.95% Notes due 2029        
Non-Current Debt        
Stated interest rate (as a percent) 6.95% 6.95%    
6.95% Notes due 2029 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 299      
6.95% Notes due 2029 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 334      
2.700% Notes Due February 2029        
Non-Current Debt        
Stated interest rate (as a percent) 2.70% 2.70%    
Debt instrument, face amount | €   € 600,000,000    
Foreign exchange rate 1.1704 1.1704    
2.700% Notes Due February 2029 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 706      
2.700% Notes Due February 2029 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 708      
1.30% Notes due 2030        
Non-Current Debt        
Stated interest rate (as a percent) 1.30% 1.30%    
1.30% Notes due 2030 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 1,676      
1.30% Notes due 2030 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 1,521      
4.70% Notes due 2030        
Non-Current Debt        
Stated interest rate (as a percent) 4.70% 4.70%    
4.70% Notes due 2030 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 995      
4.70% Notes due 2030 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 1,022      
4.90% Notes due 2031        
Non-Current Debt        
Stated interest rate (as a percent) 4.90% 4.90%    
4.90% Notes due 2031 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 1,146      
4.90% Notes due 2031 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 1,189      
3.20% Notes due 2032 (700MM Euro 1.0721)        
Non-Current Debt        
Stated interest rate (as a percent) 3.20% 3.20%    
Debt instrument, face amount | €   € 700,000,000    
Foreign exchange rate 1.1704 1.1704    
3.20% Notes due 2032 (700MM Euro 1.0721) | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 821      
3.20% Notes due 2032 (700MM Euro 1.0721) | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 834      
4.85% Notes Due 2032        
Non-Current Debt        
Stated interest rate (as a percent) 4.85% 4.85%    
4.85% Notes Due 2032 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 1,242      
4.85% Notes Due 2032 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 1,281      
4.95% Notes due 2033        
Non-Current Debt        
Stated interest rate (as a percent) 4.95% 4.95%    
4.95% Notes due 2033 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 499      
4.95% Notes due 2033 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 517      
4.375% Notes due 2033        
Non-Current Debt        
Stated interest rate (as a percent) 4.375% 4.375%    
4.375% Notes due 2033 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 853      
4.375% Notes due 2033 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt 847      
3.050% Notes Due February 2033 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 822      
Stated interest rate (as a percent) 3.05% 3.05%    
Debt instrument, face amount | €   € 700,000,000    
Foreign exchange rate 1.1704 1.1704    
3.050% Notes Due February 2033 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 822      
4.95% Notes due 2034        
Non-Current Debt        
Stated interest rate (as a percent) 4.95% 4.95%    
4.95% Notes due 2034 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 847      
4.95% Notes due 2034 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt 880      
1.650% Notes due 2035 (1.5B Euro 1.1704) | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 1,756      
Stated interest rate (as a percent) 1.65% 1.65%    
Debt instrument, face amount | €   € 1,500,000,000    
Foreign exchange rate 1.1704 1.1704    
1.650% Notes due 2035 (1.5B Euro 1.1704) | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 1,528      
5.00% Notes due 2035        
Non-Current Debt        
Stated interest rate (as a percent) 5.00% 5.00%    
5.00% Notes due 2035 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 1,244      
5.00% Notes due 2035 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 1,282      
3.35% Notes Due 2036 (800MM Euro 1.0721)        
Non-Current Debt        
Stated interest rate (as a percent) 3.35% 3.35%    
Debt instrument, face amount | €   € 800,000,000    
Foreign exchange rate 1.1704 1.1704    
3.35% Notes Due 2036 (800MM Euro 1.0721) | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 937      
3.35% Notes Due 2036 (800MM Euro 1.0721) | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 939      
3.587% Notes due 2036        
Non-Current Debt        
Stated interest rate (as a percent) 3.587% 3.587%    
3.587% Notes due 2036 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 905      
3.587% Notes due 2036 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 902      
5.95% Notes due 2037        
Non-Current Debt        
Stated interest rate (as a percent) 5.95% 5.95%    
5.95% Notes due 2037 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 994      
5.95% Notes due 2037 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 1,103      
3.625% Notes due 2037        
Non-Current Debt        
Stated interest rate (as a percent) 3.625% 3.625%    
3.625% Notes due 2037 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 1,396      
3.625% Notes due 2037 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 1,334      
3.350% Notes Due February 2037        
Non-Current Debt        
Stated interest rate (as a percent) 3.35% 3.35%    
Debt instrument, face amount | €   € 1,000,000,000.0    
Foreign exchange rate 1.1704 1.1704    
3.350% Notes Due February 2037 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 1,175      
3.350% Notes Due February 2037 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 1,160      
3.40% Notes due 2038        
Non-Current Debt        
Stated interest rate (as a percent) 3.40% 3.40%    
3.40% Notes due 2038 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 993      
3.40% Notes due 2038 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 857      
5.85% Notes due 2038        
Non-Current Debt        
Stated interest rate (as a percent) 5.85% 5.85%    
5.85% Notes due 2038 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 697      
5.85% Notes due 2038 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 761      
4.50% Notes due 2040        
Non-Current Debt        
Stated interest rate (as a percent) 4.50% 4.50%    
4.50% Notes due 2040 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 542      
4.50% Notes due 2040 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 523      
2.10% Notes due 2040        
Non-Current Debt        
Stated interest rate (as a percent) 2.10% 2.10%    
2.10% Notes due 2040 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 885      
2.10% Notes due 2040 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 684      
4.85% Notes due 2041        
Non-Current Debt        
Stated interest rate (as a percent) 4.85% 4.85%    
4.85% Notes due 2041 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 298      
4.85% Notes due 2041 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 291      
4.50% Notes due 2043        
Non-Current Debt        
Stated interest rate (as a percent) 4.50% 4.50%    
4.50% Notes due 2043 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 496      
4.50% Notes due 2043 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 459      
3.55% Notes Due 2044 (1.0B Euro 1.0721)        
Non-Current Debt        
Stated interest rate (as a percent) 3.55% 3.55%    
Debt instrument, face amount | €   € 1,000,000,000.0    
Foreign exchange rate 1.1704 1.1704    
3.55% Notes Due 2044 (1.0B Euro 1.0721) | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 1,103      
3.55% Notes Due 2044 (1.0B Euro 1.0721) | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 1,135      
3.600% Notes Due February 2045        
Non-Current Debt        
Stated interest rate (as a percent) 3.60% 3.60%    
Debt instrument, face amount | €   € 700,000,000    
Foreign exchange rate 1.1704 1.1704    
3.600% Notes Due February 2045 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 819      
3.600% Notes Due February 2045 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 792      
3.73% Notes due 2046        
Non-Current Debt        
Stated interest rate (as a percent) 3.73% 3.73%    
3.73% Notes due 2046 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 1,979      
3.73% Notes due 2046 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 1,592      
3.75% Notes due 2047        
Non-Current Debt        
Stated interest rate (as a percent) 3.75% 3.75%    
3.75% Notes due 2047 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 863      
3.75% Notes due 2047 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 798      
3.50% Notes due 2048        
Non-Current Debt        
Stated interest rate (as a percent) 3.50% 3.50%    
3.50% Notes due 2048 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 744      
3.50% Notes due 2048 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 567      
2.25% Notes due 2050        
Non-Current Debt        
Stated interest rate (as a percent) 2.25% 2.25%    
2.25% Notes due 2050 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 851      
2.25% Notes due 2050 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 580      
5.25% Notes due 2054        
Non-Current Debt        
Stated interest rate (as a percent) 5.25% 5.25%    
5.25% Notes due 2054 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 843      
5.25% Notes due 2054 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 837      
3.700% Notes Due February 2055        
Non-Current Debt        
Stated interest rate (as a percent) 3.70% 3.70%    
Debt instrument, face amount | €   € 1,000,000,000.0    
Foreign exchange rate 1.1704 1.1704    
3.700% Notes Due February 2055 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 1,172      
3.700% Notes Due February 2055 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 1,118      
2.45% Notes due 2060        
Non-Current Debt        
Stated interest rate (as a percent) 2.45% 2.45%    
2.45% Notes due 2060 | Carrying Amount        
Non-Current Debt        
Non-Current Debt $ 1,102      
2.45% Notes due 2060 | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt 694      
Other | Carrying Amount        
Non-Current Debt        
Non-Current Debt 85      
Other | Estimated Fair Value        
Non-Current Debt        
Non-Current Debt $ 88      
v3.25.2
Income Taxes (Details) - USD ($)
$ in Billions
 3 Months Ended 6 Months Ended
Jul. 24, 2025
Mar. 30, 2025
Jun. 30, 2024
Jun. 29, 2025
Jun. 30, 2024
Income Tax Contingency          
Worldwide effective income tax rate (as a percent)       17.80% 16.10%
Effective income tax rate reconciliation, tax settlement, percent       22.00% 22.00%
Unrecognized tax benefits       $ 2.2  
Scenario, Forecast          
Income Tax Contingency          
Increase (Decrease) in Deferred Income Taxes $ 1.0        
Talc | Consumer          
Income Tax Contingency          
Reversal of fee expense   $ 7.0   $ 7.0  
Litigation expense     $ 0.3   $ 3.0
v3.25.2
Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 29, 2025
Jun. 30, 2024
Jun. 29, 2025
Jun. 30, 2024
Retirement Plans        
Components of net periodic benefit cost        
Service cost $ 219 $ 222 $ 433 $ 446
Interest cost 356 351 707 703
Expected return on plan assets (599) (639) (1,186) (1,281)
Amortization of prior service cost/‍(credit) (46) (46) (92) (92)
Recognized actuarial (gains)/losses 85 44 168 87
Curtailments and settlements 0 (8) 0 (8)
Special termination benefits 1 0 1 0
Net periodic benefit cost/(credit) 16 (76) 31 (145)
Other Benefit Plans        
Components of net periodic benefit cost        
Service cost 72 69 144 138
Interest cost 53 52 107 104
Expected return on plan assets (1) (1) (3) (3)
Amortization of prior service cost/‍(credit) (1) (1) (1) (1)
Recognized actuarial (gains)/losses 15 13 31 26
Curtailments and settlements 0 0 0 0
Special termination benefits 0 0 0 0
Net periodic benefit cost/(credit) $ 138 $ 132 $ 278 $ 264
v3.25.2
Pensions and Other Benefit Plans (Details)
$ in Millions
 6 Months Ended
Jun. 29, 2025
USD ($)
U.S.  
Defined Benefit Plan Disclosure [Line Items]  
Contribution to pension plans $ 69
Foreign Plan  
Defined Benefit Plan Disclosure [Line Items]  
Contribution to pension plans $ 8
v3.25.2
Accumulated Other Comprehensive Income (Details)
$ in Millions
 6 Months Ended
Jun. 29, 2025
USD ($)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Beginning balance $ 71,490
Net change (2,564)
Ending balance 78,473
Foreign Currency Translation  
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Beginning balance (8,441)
Net change (3,739)
Ending balance (12,180)
Gain/ (Loss) On Securities  
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Beginning balance 1
Net change (1)
Ending balance 0
Employee Benefit Plans  
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Beginning balance (1,551)
Net change 85
Ending balance (1,466)
Gain/ (Loss) On Derivatives & Hedges  
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Beginning balance (1,750)
Net change 1,091
Ending balance (659)
Total Accumulated Other Comprehensive Income/(Loss)  
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Beginning balance (11,741)
Ending balance $ (14,305)
v3.25.2
Earnings Per Share (Details) - $ / shares
 3 Months Ended 6 Months Ended
Jun. 29, 2025
Jun. 30, 2024
Jun. 29, 2025
Jun. 30, 2024
Reconciliation of basic net earnings per share to diluted net earnings per share        
Total net earnings per share - basic (in dollars per share) $ 2.30 $ 1.95 $ 6.87 $ 3.30
Average shares outstanding — basic 2,406,300,000 2,406,800,000 2,406,700,000 2,407,500,000
Potential shares exercisable under stock option plans 64,600,000 62,600,000 67,000,000.0 79,300,000
Less: shares which could be repurchased under treasury stock method (51,800,000) (47,400,000) (50,400,000) (58,300,000)
Average shares outstanding — diluted 2,419,100,000 2,422,000,000 2,423,300,000 2,428,500,000
Total net earnings per share - diluted (in dollars per share) $ 2.29 $ 1.93 $ 6.82 $ 3.27
Antidilutive securities excluded from computation of earnings per share, amount 66.3 72.2 63.3 53.8
v3.25.2
Segments of Business and Geographic Areas - Narrative (Details)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 29, 2025
USD ($)
Jun. 30, 2024
USD ($)
Jun. 29, 2025
USD ($)
segment
Jun. 30, 2024
USD ($)
Segment Reporting [Abstract]        
Number of operating segments | segment     2  
Acquisition related costs $ 200      
Restructuring (Note 12) $ 64 $ (13) $ 81 $ 151
Equity Securities, FV-NI, Gain (Loss)   $ 400   $ 400
v3.25.2
Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 29, 2025
Jun. 30, 2024
Jun. 29, 2025
Jun. 30, 2024
Sales by segment of business        
Sales to customers $ 23,743 $ 22,447 $ 45,636 $ 43,830
Percent Change (as a percent) 5.80%   4.10%  
U.S.        
Sales by segment of business        
Sales to customers $ 13,544 12,569 $ 25,849 24,189
Percent Change (as a percent) 7.80%   6.90%  
International        
Sales by segment of business        
Sales to customers $ 10,199 9,878 $ 19,787 19,641
Percent Change (as a percent) 3.20%   0.70%  
Innovative Medicine        
Sales by segment of business        
Sales to customers $ 15,202 14,490 $ 29,075 28,052
Percent Change (as a percent) 4.90%   3.60%  
Innovative Medicine | U.S.        
Sales by segment of business        
Sales to customers $ 9,161 8,510 $ 17,253 16,122
Percent Change (as a percent) 7.60%   7.00%  
Innovative Medicine | International        
Sales by segment of business        
Sales to customers $ 6,041 5,980 $ 11,822 11,930
Percent Change (as a percent) 1.00%   (0.90%)  
Innovative Medicine | Oncology        
Sales by segment of business        
Sales to customers $ 6,312 5,090 $ 11,990 9,904
Percent Change (as a percent) 24.00%   21.10%  
Innovative Medicine | Oncology | U.S.        
Sales by segment of business        
Sales to customers $ 3,385 2,636 $ 6,398 5,019
Percent Change (as a percent) 28.40%   27.50%  
Innovative Medicine | Oncology | International        
Sales by segment of business        
Sales to customers $ 2,928 2,455 $ 5,592 4,885
Percent Change (as a percent) 19.30%   14.50%  
Innovative Medicine | Oncology | CARVYKTI        
Sales by segment of business        
Sales to customers $ 439 186 $ 808 343
Innovative Medicine | Oncology | CARVYKTI | U.S.        
Sales by segment of business        
Sales to customers 358 167 676 307
Innovative Medicine | Oncology | CARVYKTI | International        
Sales by segment of business        
Sales to customers 81 20 132 36
Innovative Medicine | Oncology | DARZALEX        
Sales by segment of business        
Sales to customers $ 3,539 2,878 $ 6,776 5,570
Percent Change (as a percent) 23.00%   21.70%  
Innovative Medicine | Oncology | DARZALEX | U.S.        
Sales by segment of business        
Sales to customers $ 2,017 1,641 $ 3,846 3,105
Percent Change (as a percent) 23.00%   23.90%  
Innovative Medicine | Oncology | DARZALEX | International        
Sales by segment of business        
Sales to customers $ 1,521 1,237 $ 2,930 2,465
Percent Change (as a percent) 23.00%   18.90%  
Innovative Medicine | Oncology | ERLEADA        
Sales by segment of business        
Sales to customers $ 908 736 $ 1,679 1,425
Percent Change (as a percent) 23.40%   17.80%  
Innovative Medicine | Oncology | ERLEADA | U.S.        
Sales by segment of business        
Sales to customers $ 378 318 $ 670 603
Percent Change (as a percent) 18.60%   11.00%  
Innovative Medicine | Oncology | ERLEADA | International        
Sales by segment of business        
Sales to customers $ 530 418 $ 1,009 822
Percent Change (as a percent) 27.00%   22.90%  
Innovative Medicine | Oncology | IMBRUVICA        
Sales by segment of business        
Sales to customers $ 735 770 $ 1,444 1,554
Percent Change (as a percent) (4.50%)   (7.00%)  
Innovative Medicine | Oncology | IMBRUVICA | U.S.        
Sales by segment of business        
Sales to customers $ 239 246 $ 474 511
Percent Change (as a percent) (2.70%)   (7.30%)  
Innovative Medicine | Oncology | IMBRUVICA | International        
Sales by segment of business        
Sales to customers $ 496 525 $ 970 1,043
Percent Change (as a percent) (5.40%)   (6.90%)  
Innovative Medicine | Oncology | RYBREVANT + LAZCLUZE        
Sales by segment of business        
Sales to customers $ 179 69 $ 320 116
Innovative Medicine | Oncology | RYBREVANT + LAZCLUZE | U.S.        
Sales by segment of business        
Sales to customers 139 52 252 88
Innovative Medicine | Oncology | RYBREVANT + LAZCLUZE | International        
Sales by segment of business        
Sales to customers 41 17 69 28
Innovative Medicine | Oncology | TALVEY        
Sales by segment of business        
Sales to customers $ 106 69 $ 192 127
Percent Change (as a percent) 55.00%   52.00%  
Innovative Medicine | Oncology | TALVEY | U.S.        
Sales by segment of business        
Sales to customers $ 82 59 $ 150 109
Percent Change (as a percent) 38.00%   36.70%  
Innovative Medicine | Oncology | TALVEY | International        
Sales by segment of business        
Sales to customers $ 24 9 $ 42 17
Innovative Medicine | Oncology | Tecvayli        
Sales by segment of business        
Sales to customers $ 166 135 $ 317 268
Percent Change (as a percent) 23.10%   18.20%  
Innovative Medicine | Oncology | Tecvayli | U.S.        
Sales by segment of business        
Sales to customers $ 114 104 $ 219 205
Percent Change (as a percent) 8.20%   6.60%  
Innovative Medicine | Oncology | Tecvayli | International        
Sales by segment of business        
Sales to customers $ 52 30 $ 98 63
Percent Change (as a percent) 74.80%   56.00%  
Innovative Medicine | Oncology | ZYTIGA        
Sales by segment of business        
Sales to customers $ 145 165 $ 270 346
Percent Change (as a percent) (11.60%)   (21.70%)  
Innovative Medicine | Oncology | ZYTIGA | U.S.        
Sales by segment of business        
Sales to customers $ 6 11 $ 13 20
Percent Change (as a percent) (38.90%)   (31.90%)  
Innovative Medicine | Oncology | ZYTIGA | International        
Sales by segment of business        
Sales to customers $ 139 154 $ 257 326
Percent Change (as a percent) (9.80%)   (21.10%)  
Innovative Medicine | Oncology | Other Oncology        
Sales by segment of business        
Sales to customers $ 93 83 $ 182 156
Percent Change (as a percent) 11.70%   16.40%  
Innovative Medicine | Oncology | Other Oncology | U.S.        
Sales by segment of business        
Sales to customers $ 50 37 $ 97 70
Percent Change (as a percent) 36.90%   39.80%  
Innovative Medicine | Oncology | Other Oncology | International        
Sales by segment of business        
Sales to customers $ 42 45 $ 84 86
Percent Change (as a percent) (8.70%)   (2.50%)  
Innovative Medicine | Immunology        
Sales by segment of business        
Sales to customers $ 3,993 4,722 $ 7,700 8,969
Percent Change (as a percent) (15.40%)   (14.10%)  
Innovative Medicine | Immunology | U.S.        
Sales by segment of business        
Sales to customers $ 2,505 2,978 $ 4,701 5,431
Percent Change (as a percent) (15.90%)   (13.40%)  
Innovative Medicine | Immunology | International        
Sales by segment of business        
Sales to customers $ 1,489 1,744 $ 2,999 3,538
Percent Change (as a percent) (14.60%)   (15.20%)  
Innovative Medicine | Immunology | REMICADE        
Sales by segment of business        
Sales to customers $ 455 393 $ 922 827
Percent Change (as a percent) 15.90%   11.50%  
Innovative Medicine | Immunology | REMICADE | U.S.        
Sales by segment of business        
Sales to customers $ 283 231 $ 597 497
Percent Change (as a percent) 22.50%   20.10%  
Innovative Medicine | Immunology | REMICADE | U.S. Exports        
Sales by segment of business        
Sales to customers $ 34 35 $ 44 62
Percent Change (as a percent) (2.60%)   (28.70%)  
Innovative Medicine | Immunology | REMICADE | International        
Sales by segment of business        
Sales to customers $ 138 127 $ 281 268
Percent Change (as a percent) 8.60%   4.80%  
Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA        
Sales by segment of business        
Sales to customers $ 690 537 $ 1,349 1,091
Percent Change (as a percent) 28.60%   23.70%  
Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA | U.S.        
Sales by segment of business        
Sales to customers $ 305 267 $ 597 521
Percent Change (as a percent) 14.00%   14.40%  
Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA | International        
Sales by segment of business        
Sales to customers $ 387 270 $ 753 569
Percent Change (as a percent) 43.10%   32.20%  
Innovative Medicine | Immunology | STELARA        
Sales by segment of business        
Sales to customers $ 1,653 2,885 $ 3,278 5,336
Percent Change (as a percent) (42.70%)   (38.60%)  
Innovative Medicine | Immunology | STELARA | U.S.        
Sales by segment of business        
Sales to customers $ 1,078 1,855 $ 2,059 3,251
Percent Change (as a percent) (41.90%)   (36.70%)  
Innovative Medicine | Immunology | STELARA | International        
Sales by segment of business        
Sales to customers $ 575 1,030 $ 1,219 2,085
Percent Change (as a percent) (44.20%)   (41.50%)  
Innovative Medicine | Immunology | TREMFYA        
Sales by segment of business        
Sales to customers $ 1,186 906 $ 2,142 1,714
Percent Change (as a percent) 31.00%   25.00%  
Innovative Medicine | Immunology | TREMFYA | U.S.        
Sales by segment of business        
Sales to customers $ 796 589 $ 1,395 1,098
Percent Change (as a percent) 35.20%   27.10%  
Innovative Medicine | Immunology | TREMFYA | International        
Sales by segment of business        
Sales to customers $ 391 317 $ 747 616
Percent Change (as a percent) 23.20%   21.20%  
Innovative Medicine | Immunology | OTHER IMMUNOLOGY        
Sales by segment of business        
Sales to customers $ 8 2 $ 9 2
Innovative Medicine | Immunology | OTHER IMMUNOLOGY | U.S.        
Sales by segment of business        
Sales to customers 8 2 9 2
Innovative Medicine | Immunology | OTHER IMMUNOLOGY | International        
Sales by segment of business        
Sales to customers $ 0 0 $ 0 0
Percent Change (as a percent) 0.00%   0.00%  
Innovative Medicine | Infectious Diseases        
Sales by segment of business        
Sales to customers $ 803 965 $ 1,605 1,786
Percent Change (as a percent) (16.80%)   (10.10%)  
Innovative Medicine | Infectious Diseases | U.S.        
Sales by segment of business        
Sales to customers $ 320 334 $ 635 658
Percent Change (as a percent) (4.30%)   (3.60%)  
Innovative Medicine | Infectious Diseases | International        
Sales by segment of business        
Sales to customers $ 484 631 $ 971 1,128
Percent Change (as a percent) (23.40%)   (13.90%)  
Innovative Medicine | Infectious Diseases | EDURANT/rilpivirine        
Sales by segment of business        
Sales to customers $ 360 297 $ 718 620
Percent Change (as a percent) 21.60%   15.90%  
Innovative Medicine | Infectious Diseases | EDURANT/rilpivirine | U.S.        
Sales by segment of business        
Sales to customers $ 6 8 $ 14 16
Percent Change (as a percent) (25.40%)   (13.60%)  
Innovative Medicine | Infectious Diseases | EDURANT/rilpivirine | International        
Sales by segment of business        
Sales to customers $ 354 288 $ 704 603
Percent Change (as a percent) 23.00%   16.70%  
Innovative Medicine | Infectious Diseases | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA        
Sales by segment of business        
Sales to customers $ 396 438 $ 799 856
Percent Change (as a percent) (9.40%)   (6.60%)  
Innovative Medicine | Infectious Diseases | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | U.S.        
Sales by segment of business        
Sales to customers $ 312 321 $ 617 635
Percent Change (as a percent) (3.00%)   (2.90%)  
Innovative Medicine | Infectious Diseases | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | International        
Sales by segment of business        
Sales to customers $ 85 117 $ 183 221
Percent Change (as a percent) (27.00%)   (17.20%)  
Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES        
Sales by segment of business        
Sales to customers $ 47 233 $ 88 311
Percent Change (as a percent) (79.80%)   (71.70%)  
Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES | U.S.        
Sales by segment of business        
Sales to customers $ 2 5 $ 4 7
Percent Change (as a percent) (51.80%)   (37.40%)  
Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES | International        
Sales by segment of business        
Sales to customers $ 45 227 $ 84 304
Percent Change (as a percent) (80.50%)   (72.50%)  
Innovative Medicine | Neuroscience        
Sales by segment of business        
Sales to customers $ 2,051 1,782 $ 3,698 3,585
Percent Change (as a percent) 15.10%   3.20%  
Innovative Medicine | Neuroscience | U.S.        
Sales by segment of business        
Sales to customers $ 1,377 1,102 $ 2,345 2,156
Percent Change (as a percent) 24.90%   8.70%  
Innovative Medicine | Neuroscience | International        
Sales by segment of business        
Sales to customers $ 674 679 $ 1,353 1,428
Percent Change (as a percent) (0.80%)   (5.20%)  
Innovative Medicine | Neuroscience | CAPLYTA        
Sales by segment of business        
Sales to customers $ 211 0 $ 211 0
Innovative Medicine | Neuroscience | CAPLYTA | U.S.        
Sales by segment of business        
Sales to customers 211 0 211 0
Innovative Medicine | Neuroscience | CAPLYTA | International        
Sales by segment of business        
Sales to customers $ 0 0 $ 0 0
Percent Change (as a percent) 0.00%   0.00%  
Innovative Medicine | Neuroscience | CONCERTA / methylphenidate        
Sales by segment of business        
Sales to customers $ 164 163 $ 312 340
Percent Change (as a percent) 0.20%   (8.30%)  
Innovative Medicine | Neuroscience | CONCERTA / methylphenidate | U.S.        
Sales by segment of business        
Sales to customers $ 24 34 $ 62 75
Percent Change (as a percent) (27.70%)   (16.60%)  
Innovative Medicine | Neuroscience | CONCERTA / methylphenidate | International        
Sales by segment of business        
Sales to customers $ 139 129 $ 249 265
Percent Change (as a percent) 7.50%   (6.00%)  
Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA        
Sales by segment of business        
Sales to customers $ 992 1,054 $ 1,895 2,110
Percent Change (as a percent) (5.90%)   (10.20%)  
Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | U.S.        
Sales by segment of business        
Sales to customers $ 732 784 $ 1,357 1,549
Percent Change (as a percent) (6.70%)   (12.40%)  
Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | International        
Sales by segment of business        
Sales to customers $ 260 269 $ 537 561
Percent Change (as a percent) (3.50%)   (4.20%)  
Innovative Medicine | Neuroscience | SPRAVATO        
Sales by segment of business        
Sales to customers $ 414 271 $ 734 496
Percent Change (as a percent) 53.30%   48.10%  
Innovative Medicine | Neuroscience | SPRAVATO | U.S.        
Sales by segment of business        
Sales to customers $ 366 226 $ 642 417
Percent Change (as a percent) 61.10%   53.70%  
Innovative Medicine | Neuroscience | SPRAVATO | International        
Sales by segment of business        
Sales to customers $ 50 44 $ 93 78
Percent Change (as a percent) 12.80%   18.10%  
Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE        
Sales by segment of business        
Sales to customers $ 270 294 $ 547 639
Percent Change (as a percent) (8.40%)   (14.40%)  
Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE | U.S.        
Sales by segment of business        
Sales to customers $ 45 57 $ 73 115
Percent Change (as a percent) (23.50%)   (37.00%)  
Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE | International        
Sales by segment of business        
Sales to customers $ 226 237 $ 474 524
Percent Change (as a percent) (4.70%)   (9.50%)  
Innovative Medicine | Pulmonary Hypertension        
Sales by segment of business        
Sales to customers $ 1,113 1,039 $ 2,138 2,088
Percent Change (as a percent) 7.10%   2.40%  
Innovative Medicine | Pulmonary Hypertension | U.S.        
Sales by segment of business        
Sales to customers $ 799 743 $ 1,543 1,509
Percent Change (as a percent) 7.60%   2.30%  
Innovative Medicine | Pulmonary Hypertension | International        
Sales by segment of business        
Sales to customers $ 314 296 $ 595 579
Percent Change (as a percent) 5.80%   2.60%  
Innovative Medicine | Pulmonary Hypertension | OPSUMIT/OPSYNVI        
Sales by segment of business        
Sales to customers $ 582 548 $ 1,104 1,072
Percent Change (as a percent) 6.40%   3.00%  
Innovative Medicine | Pulmonary Hypertension | OPSUMIT/OPSYNVI | U.S.        
Sales by segment of business        
Sales to customers $ 403 376 $ 766 732
Percent Change (as a percent) 6.90%   4.60%  
Innovative Medicine | Pulmonary Hypertension | OPSUMIT/OPSYNVI | International        
Sales by segment of business        
Sales to customers $ 180 171 $ 339 340
Percent Change (as a percent) 5.40%   (0.30%)  
Innovative Medicine | Pulmonary Hypertension | UPTRAVI        
Sales by segment of business        
Sales to customers $ 476 426 $ 927 894
Percent Change (as a percent) 11.70%   3.70%  
Innovative Medicine | Pulmonary Hypertension | UPTRAVI | U.S.        
Sales by segment of business        
Sales to customers $ 382 349 $ 747 741
Percent Change (as a percent) 9.40%   0.80%  
Innovative Medicine | Pulmonary Hypertension | UPTRAVI | International        
Sales by segment of business        
Sales to customers $ 94 76 $ 180 152
Percent Change (as a percent) 22.40%   17.90%  
Innovative Medicine | Pulmonary Hypertension | Other        
Sales by segment of business        
Sales to customers $ 55 67 $ 107 123
Percent Change (as a percent) (16.90%)   (12.50%)  
Innovative Medicine | Pulmonary Hypertension | Other | U.S.        
Sales by segment of business        
Sales to customers $ 16 17 $ 31 35
Percent Change (as a percent) (12.40%)   (12.60%)  
Innovative Medicine | Pulmonary Hypertension | Other | International        
Sales by segment of business        
Sales to customers $ 40 49 $ 77 88
Percent Change (as a percent) (18.50%)   (12.40%)  
Innovative Medicine | Cardiovascular / Metabolism / Other        
Sales by segment of business        
Sales to customers $ 930 892 $ 1,943 1,721
Percent Change (as a percent) 4.20%   12.90%  
Innovative Medicine | Cardiovascular / Metabolism / Other | U.S.        
Sales by segment of business        
Sales to customers $ 776 717 $ 1,631 1,348
Percent Change (as a percent) 8.20%   21.00%  
Innovative Medicine | Cardiovascular / Metabolism / Other | International        
Sales by segment of business        
Sales to customers $ 154 176 $ 312 373
Percent Change (as a percent) (12.30%)   (16.20%)  
Innovative Medicine | Cardiovascular / Metabolism / Other | Other        
Sales by segment of business        
Sales to customers $ 309 305 $ 632 616
Percent Change (as a percent) 1.40%   2.70%  
Innovative Medicine | Cardiovascular / Metabolism / Other | Other | U.S.        
Sales by segment of business        
Sales to customers $ 155 129 $ 320 243
Percent Change (as a percent) 20.00%   31.60%  
Innovative Medicine | Cardiovascular / Metabolism / Other | Other | International        
Sales by segment of business        
Sales to customers $ 154 176 $ 312 373
Percent Change (as a percent) (12.30%)   (16.20%)  
Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO        
Sales by segment of business        
Sales to customers $ 621 587 $ 1,311 1,105
Percent Change (as a percent) 5.60%   18.60%  
Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO | U.S.        
Sales by segment of business        
Sales to customers $ 621 587 $ 1,311 1,105
Percent Change (as a percent) 5.60%   18.60%  
Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO | International        
Sales by segment of business        
Sales to customers $ 0 0 $ 0 0
Percent Change (as a percent) 0.00%   0.00%  
MEDTECH        
Sales by segment of business        
Sales to customers $ 8,541 7,957 $ 16,561 15,778
Percent Change (as a percent) 7.30%   5.00%  
MEDTECH | U.S.        
Sales by segment of business        
Sales to customers $ 4,383 4,059 $ 8,596 8,067
Percent Change (as a percent) 8.00%   6.60%  
MEDTECH | International        
Sales by segment of business        
Sales to customers $ 4,158 3,898 $ 7,965 7,711
Percent Change (as a percent) 6.70%   3.30%  
MEDTECH | Cardiovascular        
Sales by segment of business        
Sales to customers $ 2,313 1,873 $ 4,416 3,679
Percent Change (as a percent) 23.50%   20.00%  
MEDTECH | Cardiovascular | U.S.        
Sales by segment of business        
Sales to customers $ 1,364 1,119 $ 2,625 2,144
Percent Change (as a percent) 21.90%   22.40%  
MEDTECH | Cardiovascular | International        
Sales by segment of business        
Sales to customers $ 948 753 $ 1,790 1,534
Percent Change (as a percent) 25.90%   16.70%  
MEDTECH | ELECTROPHYSIOLOGY        
Sales by segment of business        
Sales to customers $ 1,468 1,323 $ 2,791 2,667
Percent Change (as a percent) 11.00%   4.70%  
MEDTECH | ELECTROPHYSIOLOGY | U.S.        
Sales by segment of business        
Sales to customers $ 741 705 $ 1,425 1,397
Percent Change (as a percent) 5.10%   2.00%  
MEDTECH | ELECTROPHYSIOLOGY | International        
Sales by segment of business        
Sales to customers $ 728 618 $ 1,366 1,270
Percent Change (as a percent) 17.80%   7.60%  
MEDTECH | ABIOMED        
Sales by segment of business        
Sales to customers $ 448 379 $ 868 750
Percent Change (as a percent) 18.20%   15.70%  
MEDTECH | ABIOMED | U.S.        
Sales by segment of business        
Sales to customers $ 360 309 $ 699 612
Percent Change (as a percent) 16.60%   14.20%  
MEDTECH | ABIOMED | International        
Sales by segment of business        
Sales to customers $ 89 72 $ 170 139
Percent Change (as a percent) 25.00%   22.40%  
MEDTECH | Shockwave        
Sales by segment of business        
Sales to customers $ 292 77 $ 550 77
MEDTECH | Shockwave | U.S.        
Sales by segment of business        
Sales to customers 233 77 439 77
MEDTECH | Shockwave | International        
Sales by segment of business        
Sales to customers 58 0 110 0
MEDTECH | Other Cardiovascular        
Sales by segment of business        
Sales to customers $ 104 93 $ 207 185
Percent Change (as a percent) 10.80%   11.70%  
MEDTECH | Other Cardiovascular | U.S.        
Sales by segment of business        
Sales to customers $ 31 29 $ 63 59
Percent Change (as a percent) 5.40%   6.30%  
MEDTECH | Other Cardiovascular | International        
Sales by segment of business        
Sales to customers $ 72 64 $ 144 126
Percent Change (as a percent) 13.40%   14.20%  
MEDTECH | Orthopaedics        
Sales by segment of business        
Sales to customers $ 2,305 2,312 $ 4,546 4,652
Percent Change (as a percent) (0.30%)   (2.30%)  
MEDTECH | Orthopaedics | U.S.        
Sales by segment of business        
Sales to customers $ 1,420 1,422 $ 2,804 2,870
Percent Change (as a percent) (0.20%)   (2.30%)  
MEDTECH | Orthopaedics | International        
Sales by segment of business        
Sales to customers $ 885 890 $ 1,742 1,782
Percent Change (as a percent) (0.50%)   (2.20%)  
MEDTECH | Orthopaedics | HIPS        
Sales by segment of business        
Sales to customers $ 421 417 $ 830 839
Percent Change (as a percent) 1.00%   (1.10%)  
MEDTECH | Orthopaedics | HIPS | U.S.        
Sales by segment of business        
Sales to customers $ 271 265 $ 534 535
Percent Change (as a percent) 2.10%   (0.20%)  
MEDTECH | Orthopaedics | HIPS | International        
Sales by segment of business        
Sales to customers $ 150 152 $ 296 304
Percent Change (as a percent) (1.00%)   (2.50%)  
MEDTECH | Orthopaedics | KNEES        
Sales by segment of business        
Sales to customers $ 389 394 $ 778 795
Percent Change (as a percent) (1.10%)   (2.00%)  
MEDTECH | Orthopaedics | KNEES | U.S.        
Sales by segment of business        
Sales to customers $ 226 230 $ 457 472
Percent Change (as a percent) (1.90%)   (3.10%)  
MEDTECH | Orthopaedics | KNEES | International        
Sales by segment of business        
Sales to customers $ 164 163 $ 322 323
Percent Change (as a percent) 0.00%   (0.50%)  
MEDTECH | Orthopaedics | TRAUMA        
Sales by segment of business        
Sales to customers $ 768 759 $ 1,540 1,524
Percent Change (as a percent) 1.20%   1.10%  
MEDTECH | Orthopaedics | TRAUMA | U.S.        
Sales by segment of business        
Sales to customers $ 501 498 $ 1,003 1,002
Percent Change (as a percent) 0.70%   0.10%  
MEDTECH | Orthopaedics | TRAUMA | International        
Sales by segment of business        
Sales to customers $ 267 260 $ 537 521
Percent Change (as a percent) 2.20%   2.90%  
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER        
Sales by segment of business        
Sales to customers $ 727 743 $ 1,398 1,495
Percent Change (as a percent) (2.10%)   (6.50%)  
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER | U.S.        
Sales by segment of business        
Sales to customers $ 422 430 $ 810 862
Percent Change (as a percent) (1.70%)   (6.00%)  
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER | International        
Sales by segment of business        
Sales to customers $ 305 314 $ 588 634
Percent Change (as a percent) (2.70%)   (7.20%)  
MEDTECH | Surgery        
Sales by segment of business        
Sales to customers $ 2,555 2,488 $ 4,951 4,904
Percent Change (as a percent) 2.70%   1.00%  
MEDTECH | Surgery | U.S.        
Sales by segment of business        
Sales to customers $ 1,043 995 $ 2,045 1,982
Percent Change (as a percent) 4.80%   3.20%  
MEDTECH | Surgery | International        
Sales by segment of business        
Sales to customers $ 1,512 1,493 $ 2,906 2,922
Percent Change (as a percent) 1.30%   (0.50%)  
MEDTECH | Surgery | ADVANCED        
Sales by segment of business        
Sales to customers $ 1,164 1,141 $ 2,237 2,228
Percent Change (as a percent) 2.00%   0.40%  
MEDTECH | Surgery | ADVANCED | U.S.        
Sales by segment of business        
Sales to customers $ 477 466 $ 934 912
Percent Change (as a percent) 2.20%   2.40%  
MEDTECH | Surgery | ADVANCED | International        
Sales by segment of business        
Sales to customers $ 687 675 $ 1,303 1,316
Percent Change (as a percent) 1.90%   (1.00%)  
MEDTECH | Surgery | GENERAL        
Sales by segment of business        
Sales to customers $ 1,391 1,346 $ 2,714 2,676
Percent Change (as a percent) 3.30%   1.40%  
MEDTECH | Surgery | GENERAL | U.S.        
Sales by segment of business        
Sales to customers $ 567 528 $ 1,111 1,070
Percent Change (as a percent) 7.20%   3.80%  
MEDTECH | Surgery | GENERAL | International        
Sales by segment of business        
Sales to customers $ 825 818 $ 1,603 1,606
Percent Change (as a percent) 0.90%   (0.10%)  
MEDTECH | Vision        
Sales by segment of business        
Sales to customers $ 1,369 1,285 $ 2,648 2,543
Percent Change (as a percent) 6.50%   4.10%  
MEDTECH | Vision | U.S.        
Sales by segment of business        
Sales to customers $ 557 523 $ 1,123 1,070
Percent Change (as a percent) 6.50%   4.90%  
MEDTECH | Vision | International        
Sales by segment of business        
Sales to customers $ 813 763 $ 1,526 1,473
Percent Change (as a percent) 6.50%   3.60%  
MEDTECH | Vision | CONTACT LENSES / OTHER        
Sales by segment of business        
Sales to customers $ 965 918 $ 1,884 1,828
Percent Change (as a percent) 5.10%   3.10%  
MEDTECH | Vision | CONTACT LENSES / OTHER | U.S.        
Sales by segment of business        
Sales to customers $ 429 409 $ 881 847
Percent Change (as a percent) 4.80%   3.90%  
MEDTECH | Vision | CONTACT LENSES / OTHER | International        
Sales by segment of business        
Sales to customers $ 536 509 $ 1,003 981
Percent Change (as a percent) 5.40%   2.30%  
MEDTECH | Vision | SURGICAL        
Sales by segment of business        
Sales to customers $ 403 367 $ 764 715
Percent Change (as a percent) 9.90%   6.90%  
MEDTECH | Vision | SURGICAL | U.S.        
Sales by segment of business        
Sales to customers $ 128 113 $ 242 223
Percent Change (as a percent) 12.60%   8.50%  
MEDTECH | Vision | SURGICAL | International        
Sales by segment of business        
Sales to customers $ 277 $ 254 $ 523 $ 492
Percent Change (as a percent) 8.80%   6.20%  
v3.25.2
Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 29, 2025
Mar. 30, 2025
Jun. 30, 2024
Jun. 29, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]          
Sales to customers (Note 9) $ 23,743   $ 22,447 $ 45,636 $ 43,830
Cost of products sold 7,628   6,869 14,985 13,380
Gross Profit 16,115   15,578 30,651 30,450
Selling, marketing and administrative expenses 5,889   5,681 11,001 10,938
Research and development expense 3,516   3,440 6,741 6,982
Other (income) expense, net (107)   (653) 7,214 (3,057)
Earnings before provision for taxes on income 6,491   5,748 20,122 9,462
Less: Expense not allocated to segments 265   800 (6,735) 3,575
Restructuring charges 64   (13) 81 151
Acquisition related costs 200        
Innovative Medicine          
Segment Reporting Information [Line Items]          
Sales to customers (Note 9) 15,202   14,490 29,075 28,052
Restructuring charges         100
Impairment of intangible assets, finite-lived     200   200
Restructuring income     100    
Acquisition related costs       200  
MedTech          
Segment Reporting Information [Line Items]          
Sales to customers (Note 9) 8,541   7,957 16,561 15,778
Restructuring charges 100   100 100 100
Acquisition related costs     400 100 500
Consumer | Talc          
Segment Reporting Information [Line Items]          
Litigation expense     300   3,000
Reversal of fee expense   $ 7,000   7,000  
Operating Segments          
Segment Reporting Information [Line Items]          
Earnings before provision for taxes on income 6,756   6,548 13,387 13,037
Restructuring charges 79   (11) 134 160
Operating Segments | Innovative Medicine          
Segment Reporting Information [Line Items]          
Sales to customers (Note 9) 15,202   14,490 29,075 28,052
Cost of products sold 3,978   3,603 7,998 6,973
Selling, marketing and administrative expenses 2,789   2,665 5,050 5,103
Research and development expense 2,869   2,722 5,417 5,618
Other (income) expense, net 14   41 (152) (70)
Earnings before provision for taxes on income 5,552   5,459 10,762 10,428
Amortization 800   700 1,400 1,400
Restructuring charges 0   (63) 0 81
Operating Segments | MedTech          
Segment Reporting Information [Line Items]          
Sales to customers (Note 9) 8,541   7,957 16,561 15,778
Cost of products sold 3,638   3,248 6,964 6,368
Selling, marketing and administrative expenses 2,862   2,671 5,518 5,253
Research and development expense 647   718 1,324 1,364
Other (income) expense, net 190   231 130 184
Earnings before provision for taxes on income 1,204   1,089 2,625 2,609
Amortization 500   400 1,000 800
Restructuring charges $ 50   $ 52 $ 105 $ 79
v3.25.2
Segments of Business and Geographic Areas - Identifiable Assets (Details) - USD ($)
$ in Millions
Jun. 29, 2025
Dec. 29, 2024
Segment Reporting Information [Line Items]    
Assets $ 193,389 $ 180,104
Segments Total    
Segment Reporting Information [Line Items]    
Assets 162,232 141,392
Operating Segments | Innovative Medicine    
Segment Reporting Information [Line Items]    
Assets 75,487 57,070
Operating Segments | MEDTECH    
Segment Reporting Information [Line Items]    
Assets 86,745 84,322
Corporate, Non-Segment | General Corporate    
Segment Reporting Information [Line Items]    
Assets $ 31,157 $ 38,712
v3.25.2
Segments of Business and Geographic Areas - Additions to Property, Plan & Equipment and Depreciation and Amortization (Details) - USD ($)
$ in Millions
 6 Months Ended
Jun. 29, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]    
Additions to Property, Plant & Equipment $ 1,838 $ 1,783
Depreciation and Amortization 3,715 3,597
Segments Total    
Segment Reporting Information [Line Items]    
Additions to Property, Plant & Equipment 1,758 1,627
Depreciation and Amortization 3,603 3,413
Operating Segments | Innovative Medicine    
Segment Reporting Information [Line Items]    
Additions to Property, Plant & Equipment 687 553
Depreciation and Amortization 1,925 1,861
Operating Segments | MEDTECH    
Segment Reporting Information [Line Items]    
Additions to Property, Plant & Equipment 1,071 1,074
Depreciation and Amortization 1,678 1,552
Corporate, Non-Segment | General Corporate    
Segment Reporting Information [Line Items]    
Additions to Property, Plant & Equipment 80 156
Depreciation and Amortization $ 112 $ 184
v3.25.2
Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 29, 2025
Jun. 30, 2024
Jun. 29, 2025
Jun. 30, 2024
Sales by geographic area        
Sales $ 23,743 $ 22,447 $ 45,636 $ 43,830
Percent Change 5.80%   4.10%  
United States        
Sales by geographic area        
Sales $ 13,544 12,569 $ 25,849 24,189
Percent Change 7.80%   6.90%  
Europe        
Sales by geographic area        
Sales $ 5,387 5,214 $ 10,497 10,377
Percent Change 3.30%   1.10%  
Western Hemisphere, excluding U.S.        
Sales by geographic area        
Sales $ 1,206 1,212 $ 2,373 2,406
Percent Change (0.50%)   (1.30%)  
Asia-Pacific, Africa        
Sales by geographic area        
Sales $ 3,606 $ 3,452 $ 6,917 $ 6,858
Percent Change 4.40%   0.90%  
v3.25.2
Acquisitions and Divestitures - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 6 Months Ended
Apr. 02, 2025
Jun. 20, 2024
May 31, 2024
Mar. 07, 2024
Jun. 29, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 29, 2025
Jun. 30, 2024
Dec. 29, 2024
Business Combination [Line Items]                    
Acquisition related costs         $ 200          
Payments to acquire businesses               $ 14,458 $ 14,807  
Goodwill, related to acquisitions               2,876    
Contingent consideration         1,157     1,157   $ 1,217
Goodwill (Note 3)         48,117     $ 48,117   $ 44,200
Proceeds from sale of business           $ 300 $ 200      
Intra-Cellular Therapies, Inc.                    
Business Combination [Line Items]                    
Share price (in dollars per share) $ 132.00                  
Consideration transferred $ 14,500                  
Acquisition related costs 200                  
Business Combination, Integration-Related Cost, Expense 100                  
Liabilities assumed 3,000                  
Amortizable intangibles asset 5,200                  
Goodwill (Note 3) $ 2,900                  
Proteologix                    
Business Combination [Line Items]                    
Acquisition related costs         0          
Payments to acquire businesses   $ 800                
Assets acquired   1,200                
Goodwill acquired   900                
Goodwill, related to acquisitions   300                
Liabilities assumed   300                
Contingent consideration   $ 100                
Shockwave Medical, Inc.                    
Business Combination [Line Items]                    
Payments to acquire businesses     $ 11,500              
Assets acquired     14,400              
Goodwill acquired     600              
Liabilities assumed     2,900              
Payments to acquire businesses, gross     12,600              
Amortizable intangibles asset     5,300              
Goodwill (Note 3)     7,600              
Assumed other noncurrent assets     400              
Acquired inventory     $ 500              
Ambrx                    
Business Combination [Line Items]                    
Acquisition related costs         $ 0          
Payments to acquire businesses       $ 1,800            
Assets acquired       2,300            
Goodwill acquired       1,900            
Goodwill, related to acquisitions       300            
Liabilities assumed       $ 500            
v3.25.2
Acquisitions and Divestitures - Schedule of Preliminary Amounts Recognized for Assets Acquired and Liabilities Assumed (Details)
$ in Millions
Apr. 02, 2025
USD ($)
intangibleAsset
Jun. 29, 2025
USD ($)
Dec. 29, 2024
USD ($)
Assets acquired:      
Goodwill (Note 3)   $ 48,117 $ 44,200
Intra-Cellular Therapies, Inc.      
Assets acquired:      
Cash and cash equivalents $ 200    
Marketable securities 600    
Other current & non-current assets 300    
Amortizable intangibles asset 5,200    
Acquired in-process research and development 8,300    
Goodwill (Note 3) 2,900    
Total assets acquired 17,500    
Liabilities assumed:      
Deferred taxes 2,800    
Other current & non-current liabilities 200    
Total liabilities assumed 3,000    
Total assets acquired and liabilities assumed $ 14,500    
Weighted average useful life 8 years    
Number of intangible assets acquired | intangibleAsset 2    
Probability of success factor 95.00%    
Intra-Cellular Therapies, Inc. | Minimum      
Liabilities assumed:      
Acquired finite-lived intangible assets, discount rate 11.50%    
Probability of success factor 3400.00%    
Intra-Cellular Therapies, Inc. | Maximum      
Liabilities assumed:      
Acquired finite-lived intangible assets, discount rate 12.50%    
Probability of success factor 50.00%    
v3.25.2
Legal Proceedings (Details)
$ in Millions
 1 Months Ended 3 Months Ended 6 Months Ended
May 01, 2024
USD ($)
Aug. 31, 2024
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Jul. 31, 2018
USD ($)
Mar. 30, 2025
USD ($)
Jun. 29, 2025
USD ($)
claimant
cases
Dec. 29, 2024
USD ($)
Sep. 30, 2021
cases
Jul. 04, 2021
USD ($)
May 31, 2021
cases
claimant
Physiomesh                      
Legal Proceeding (Textuals)                      
Product liability contingency, number of claimants | claimant             120        
Physiomesh | Pending Litigation                      
Legal Proceeding (Textuals)                      
Number of pending claims | cases                     3,600
Product liability contingency, number of claimants | claimant                     4,300
Number of claims within settlement agreement | cases                 3,729    
Talc                      
Legal Proceeding (Textuals)                      
Product liability contingency, number of claimants | claimant             70,030        
Opioid                      
Legal Proceeding (Textuals)                      
Loss contingency accrual                   $ 5,000  
Product liability contingency, number of claimants | claimant             3,500        
Loss contingency accrual, payment percentage             80.00%        
Opioid | Various State Courts                      
Legal Proceeding (Textuals)                      
Number of open cases | cases             27        
Opioid | Ohio Multi-District Litigation                      
Legal Proceeding (Textuals)                      
Number of open cases | cases             290        
Opioid | Federal Courts                      
Legal Proceeding (Textuals)                      
Number of open cases | cases             2        
Ingham v. Johnson & Johnson                      
Legal Proceeding (Textuals)                      
Damages awarded       $ 2,100 $ 4,700            
Damages paid     $ 2,500                
DePuy ASR U.S. | Settled Litigation                      
Legal Proceeding (Textuals)                      
Number of patients in settlement | claimant             10,000        
Talc                      
Legal Proceeding (Textuals)                      
Litigation contingency $ 6,475                    
Payment period 25 years                    
Damages sought, nominal value $ 8,000                    
Bankruptcy loss contingency, discount rate 4.40%                    
Total claims against company, percent 99.75%                    
Incremental charges           $ 5,000          
Loss contingency accrual             $ 4,000 $ 11,600      
Loss contingency accrual, nominal value               $ 13,500      
Loss contingency accrual, payment percentage             33.00%        
Solicitation period 3 months                    
Talc | Consumer                      
Legal Proceeding (Textuals)                      
Reversal of fee expense           $ 7,000 $ 7,000        
Mesothelioma and State Claims                      
Legal Proceeding (Textuals)                      
Claims settled, percent   95.00%                  
v3.25.2
Legal Proceedings - Product Liability (Details)
Jun. 29, 2025
claimant
Talc  
Loss Contingencies [Line Items]  
Product liability contingency, number of claimants 70,030
ASR  
Loss Contingencies [Line Items]  
Product liability contingency, number of claimants 40
Pinnacle Acetabular Cup System  
Loss Contingencies [Line Items]  
Product liability contingency, number of claimants 860
Pelvic Meshes  
Loss Contingencies [Line Items]  
Product liability contingency, number of claimants 5,350
Physiomesh  
Loss Contingencies [Line Items]  
Product liability contingency, number of claimants 120
Elmiron  
Loss Contingencies [Line Items]  
Product liability contingency, number of claimants 920
v3.25.2
Restructuring - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 29, 2025
Jun. 30, 2024
Jun. 29, 2025
Jun. 30, 2024
Restructuring Cost and Reserve [Line Items]        
Restructuring charges $ 64 $ (13) $ 81 $ 151
MedTech Surgery Franchise        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges $ 29      
Restructuring and related cost, expected cost, term 2 years      
MedTech Surgery Franchise | Minimum        
Restructuring Cost and Reserve [Line Items]        
Restructuring estimated cost $ 900   900  
MedTech Surgery Franchise | Maximum        
Restructuring Cost and Reserve [Line Items]        
Restructuring estimated cost 1,000   1,000  
Orthopedics Restructuring Plan        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges recorded to date 600   600  
Orthopedics Restructuring Plan | Minimum        
Restructuring Cost and Reserve [Line Items]        
Restructuring estimated cost 700   700  
Orthopedics Restructuring Plan | Maximum        
Restructuring Cost and Reserve [Line Items]        
Restructuring estimated cost $ 800   $ 800  
v3.25.2
Restructuring - Schedule of Restructuring Reserve (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 29, 2025
Jun. 30, 2024
Jun. 29, 2025
Jun. 30, 2024
Restructuring Cost and Reserve [Line Items]        
Restructuring charges $ 64 $ (13) $ 81 $ 151
Operating Segments        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges 79 (11) 134 160
MEDTECH        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges 100 100 100 100
MEDTECH | Operating Segments        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges 50 52 105 79
MEDTECH | Restructuring Charges        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges 35 50 52 70
MEDTECH | Costs of Goods and Services Sold        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges 15 2 23 9
MEDTECH | Other (income) expense        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges     30  
MedTech Surgery Franchise | Operating Segments        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges 29 0 29 0
Innovative Medicine        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges       100
Innovative Medicine | Operating Segments        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges $ 0 $ (63) $ 0 $ 81